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CHAPTER 1
INTRODUCTION
Lung cancer is the leading cancer site in males, comprising 17% of total
new cancer cases, and is the most common cause of cancer related deaths at
23%. In the United States, The American Cancer Society estimated that 222,520
Americans were diagnosed with lung cancer and 157,300 died of lung cancer in
2010 (Jemal et al. 2009, 225-249;Jemal et al. 2011, 69-90). Dreadfully, in United
States death rates from lung cancer in women are almost twice that of breast
cancer, and in men, the rate is three times greater compared to prostate cancer
(Jemal et al. 2008, 71-96;Jemal et al. 2009, 225-249;Jemal et al. 2011, 69-90).
Increasing incidence of lung cancer is associated with several risk factors
including: lifestyle choices, environmental factors, and genetic make-up, all of
which contribute to the risk of developing lung cancer. Among many risk factors,
tobacco smoke, Radon, asbestos, and arsenic exposure have been linked with
increasing rates of lung cancer.
Lung cancers are divided into two major categories as follows (Table 1):
non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC
is the most common type, accounting for (85%) of all lung cancer cases. There
are three histological subtypes of NSCLC:
a. Squamous cell carcinoma, usually found among patients with a history of
smoking; it forms in the central lung near the large airways (bronchi).

2

b. Adenocarcinoma occurs in smokers and non-smokers; it forms in the outer
region of the lung.
c. Large-cell undifferentiated carcinoma; it is a very aggressive cancer with
poor prognosis and forms in any region of the lung.
SCLCs make up only about 10 to 15 percent of all lung cancer cases but tend to
be highly aggressive. Lung cancer is difficult to treat effectively with cancer type,
size, and location determining the choice of treatment. Currently, there are many
strategies available for the treatment of lung cancer, some of which are
discussed below (Table 2) but the outcome is still disappointing.
Treatment Options for Lung Cancer
Surgery is the first line of treatment for localized non-small cell lung cancer
(NSCLC) and lung carcinoid cancers. For cancers that have grown more
extensively in the lungs, more aggressive surgery is required to remove the
cancer. If SCLC is caught before it spreads surgery is the best option. However,
surgical procedures will not excise all cancer cells from the lung, and thus
residual cancer cells must be treated with radiation therapy, chemotherapy or a
combination of the two, known as adjuvant therapy. Current chemotherapy drugs
are listed in Table 2. Additional drugs called targeted therapy have been added
recently to be specially used in combination with traditional chemotherapy.
Targeted-drug-therapy is an approach that blocks the ability of cancer cells to
grow by targeting a mutated protein or other driver oncogenes within
heterogeneous populations of cancer cells in the tumor mass. For example,
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Erlotinib is a tyrosine kinase inhibitor that blocks the activity of the epidermal
growth factor receptor (EGFR). Angiogenesis inhibitory drugs prevent cancers
from acquiring new blood vessels; examples that have been used include
Bevacizumab, which is known to block vascular endothelial growth factors
(VEGF) that activate endothelial cells to develop new blood vessels. However,
these targeted therapies only work effectively in a small subset of cancer patients
suggesting that newer therapies must be developed (Herbst and Sandler 2008,
1166-1176;Ramalingam and Belani 2008, 5-13).
Despite all recent advances in lung cancer therapy the 5-year survival rate
across all stages of lung cancer is approximately 15%. This is due to lack of
reliable and cost-effective screening techniques for early detection of lung
cancer, and thus many patients are diagnosed at advanced stages of the
disease. This results in about 90% of cancer patient’s deaths occuring from
metastasis of their primary cancer. Furthermore, resistance to anti-cancer
therapies (chemotherapy, radiation, and targeted therapies) both at the onset of
therapy and following initial therapy is a major obstacle in cancer therapies. In
other words, patients treated with conventional anti-cancer drugs may respond
initially (e.g. shrinkage in tumor mass), but over the course of the treatment
tumor mass re-grows with the acquisition of a drug-resistant phenotype. It is
believed that both de novo and acquired drug resistance is the cause of
treatment failure, which leads to tumor recur rence and subsequent metastasis
that kills lung cancer patients. The combination of this lack of cost-effective early
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diagnosis, and the intrinsic (de novo) and extrinsic (acquired) therapeutic
resistance to conventional therapy that exist in some cancer patients contribute
to dismal the outcome in the survival of patients diagnosed with lung cancer.
Therefore, to increase survival rate among lung cancer patients we need
to target metastasic processes and also develop novel therapies targeting the
surviving cancer cells after conventional existing therapy or it is necessary to
develop and employ targeted drugs that must be found or discovered based on
molecular knowledge. Hence, a deeper understanding of the molecular
mechanisms involved in drug resistance, tumor progression, and metastasis of
lung cancer cells will be the key to newer and more effective strategies for the
treatment

of

lung

cancer

with

better

treatment

outcomes

(http://www.aacr.org/home/public--media/patients--family/fact-heets/organ-sitefact-sheets/lung-cancer.aspx).
Emerging evidence suggests that the phenomenon called Epithelial to
Mesenchymal Transition (EMT), which shares some molecular characteristics
with cancer stem-like cells, contributes to treatment failure. It is important to note
that the EMT process has been implicated in the two important biological
processes that are accountable for cancer-related deaths: the progressive growth
of cancer cells to a distant organ and the acquisition of resistance to conventional
cancer therapeutics. Therefore, further mechanistic understanding of the role of
EMT in lung cancer would be very important, and such knowledge will help us in
developing novel strategies that can would interfere with EMT induced drug
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resistance and tumor metastasis. Moreover, such knowledge of which oncogenic
targets is important would be invaluable and contribute to finding drugs that could
destroy those targets. This would vastly improve the overall survival outcomes of
lung cancer patients, in particular NSCLC, which accounts for the majority of lung
cancer cases.

Epithelial to Mesenchymal Transition Phenomenon and its role in cancer:
Epithelial to Mesenchymal Transition (EMT) and Mesenchymal to
Epithelial Transition (MET) are changes in cellular phenotype where cells
transition between epithelial and mesenchymal states. Early on EMT was
recognized to be important in embryonic development, including parietal
endoderm formation and gastrulation (Thiery 2003, 740-746). EMT was also
recognized as an important process in the progression of cancer, and has been
been implicated in other human diseases.
EMT refers to a complex cellular and molecular program where epithelial
cells lose their differentiated characteristics including cell–cell adhesion, planar
and apical–basal polarity, as well as their lack of motile function. They then
acquire mesenchymal features including increased motility, invasiveness, and
resistance to apoptosis (Fig-1) (Turley et al. 2008, 280-290).
The process of EMT was first described as a cell culture phenomenon,
but its role in physiological processes was not clear (Baum, Settleman, and
Quinlan 2008, 294-308;Hugo et al. 2007, 374-383;Mani et al. 2008, 704-
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715;Thiery and Sleeman 2006, 131-142). However, the increasing awareness of
its roles in human cancers and the wealth of data that has been generated using
animal models has contributed convincing evidence in support of the existence of
EMT and MET, suggesting that the processes of EMT-MET are physiologically
relevant in both normal embryogenesis and carcinogenesis (Morel et al. 2008,
e2888;Sabbah et al. 2008, 123-151). In cancer, the processes of EMT were
found to play key roles in invasion, metastatic dissemination and the acquisition
of therapeutic resistance. In addition, EMT phenotype in cancers has been
associated with poor clinical outcomes in multiple cancer types (Polyak and
Weinberg 2009, 265-273). Moreover, EMT has been implicated in the alteration
of early-stage cancers the led to their becoming invasive malignancies (Iwano et
al. 2002, 341-350;Kang and Massague 2004, 277-279;Larue and Bellacosa
2005, 7443-7454;Yilmaz, Christofori, and Lehembre 2007, 535-541;Yu et al.
2007, 1109-1123). In addition, MET (reversal of the EMT process) is anticipated
to play a role following the tumor cells dissemination and, consequently, the
formation of distant metastases prior to rapid cancer cell growth at the metastatic
sites. Recently, MET has been recognized for the extra cellular matrix protein
versican in vitro, whereas the exogenous expression of the versican isoform V1
induced a N-cadherin to E-cadherin switch, resulting in epithelial-specific
adhesion junctions in fibroblasts, while silencing of endogenous versican
prevented MET (Sheng et al. 2006, 2009-2020). Interestingly, a different model
for the role of EMT in cancer metastasis has been proposed in which EMT and
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non-EMT cells cooperate to complete the entire process of spontaneous
metastasis (Tsuji, Ibaragi, and Hu 2009, 7135-7139).
In general, the processes of EMT in cancer are regulated by the genomic
instability of cancer cells, including genetic and epigenetic factors, and the effect
of stromal cells signaling within the cancer microenvironment, which leads to
cancer heterogeneity within the tumor mass (Fig-2) (Sabbah et al. 2008, 123151).
The EMT-phenotypic cells have been shown to share characteristics with
both stem cells and cancer stem-like cells. These findings has been supported by
several studies, showing that EMT phenotype induced by TGF-β or expression of
TWIST or SNAIL transcription factors shares stem-like cell features as
demonstrated by cell surface antigenic profiles, gene expression patterns, ability
of EMT cells to form mammospheres in culture and ductal outgrowth in
xenotransplant assays (Morel et al. 2008, e2888;Sabbah et al. 2008, 123-151).
This data was found to be correlated with the data showing that high levels of
genes associated with invasion, metastasis, and angiogenesis were indeed
found in CD44+CD24– breast cancer cells (Sheridan et al. 2006, R59;Shipitsin et
al. 2007, 259-273) further enabling these cells to invade and metastasize
(Sheridan et al. 2006, R59). Furthermore, breast cancer cells disseminated in
circulation and by the bone marrow have been found to be CD44+CD24– antigen
phenotype (Riethdorf and Pantel 2008, 140-148;Riethdorf, Wikman, and Pantel
2008, 1991-2006;Slade et al. 2009, 160-166). Moreover, Immunohistochemistry
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analysis of 479 invasive breast carcinomas showed a high expression of EMTinduced markers such as vimentin, α-smooth muscle actin, neural cadherin (ncadherin), cadherin 11, SpArC, laminin, and fascin, in addition to low levels of Ecadherin, all of which were found to be associated with basal-type breast cancers
(associated with poor prognosis and increased capability to metastatisize)
compared with other subtypes of breast cancer (Perou et al. 2000, 747752;Sorlie et al. 2001, 10869-10874). Furthermore, the acquisition of EMT (gain
of cancer stem-like cell characteristics) is also known to be associated with
insensitivity to apoptosis (Iwano et al. 2002, 341-350;Robson et al. 2006, 254264), suggesting that the reversal of these phenotypes would be important to
make cancer cells sensitive to apoptotic stimuli. For example, EpH-4 and
nMuMG murine mammary epithelial cell lines acquired resistance to ultravioletinduced apoptosis after EMT conversion by treatment with TGF-β (Robson et al.
2006, 254-264). Similar findings were shown by down-regulation in the
expression of the let-7 microRNA (miRNA) in breast cancer cell lines that led to
increased metastatic capability and therapeutic resistance, associated with the
acquisition of stem cell features consistent with EMT specific gene expression
profiles.
Several mechanisms for EMT stimulation have been identified, and
consequently numerous molecules and signaling pathways shown to be involved
in the EMT process. Examples of positive regulators of EMT include matrix
metalloproteinase 3 (MMP-3, also known as stromelysin 1) (Radisky et al. 2005,

9

123-127), hypoxia (Gort et al. 2008, 60-67), and 5-aza-cytidine (a DNA
methyltransferase inhibitor), which increased

MCF-7 breast cancer cells

invasiveness and metastasis by up-regulation of pro-invasive EMT-associated
genes (Ateeq et al. 2008, 266-278;Guo et al. 2002, 41571-41579). More
examples include chronic exposure to EGFR-TKI (Rho et al. 2009, 219-226),
HGF(Montesano et al. 1991, 901-908), and aromatic hydrocarbon (e.g.
Benzo[a]payere) (Yoshino et al. 2007, 369-374), which lead to tumor
aggressiveness and drug resistance.
Likewise, Wnt signaling can also lead to EMT by the inhibition of glycogen
synthase kinase-3β (GSK3β)-mediated phosphorylation and the degradation of
β-catenin in the cytoplasm, leading to increased β-catenin levels and its
translocation to the nucleus, where it acts as a transcription factor inducing the
expression of genes, resulting in the acquisition of EMT phenotype (Vincan and
Barker 2008, 657-663). In addition, Notch signaling has been implicated in
playing important roles in the regulation of EMT which occurs both during
embryogenesis and carcinogenesis (Bailey, Singh, and Hollingsworth 2007, 829839). The Notch signaling signally pathway, once activated, is known to crosstalk with other important signaling pathways such as Nuclear Factor-κB (NF-κB)
pathway (Wang et al. 2006, 2778-2784) and TGF-β signaling pathways during
the acquisition of EMT. In addition, emerging evidence suggests that certain
miRNAs are important regulators of many genes that are involved in the
acquisition of EMT. For example, miR-200 family (miR-200a, miR-200b, miR-
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200c), miR-141, miR-429 and miR-205 are among many miRNAs that appear to
play an important role in the acquisition of EMT (Gregory et al. 2008, 31123118;Gregory et al. 2008, 593-601;Park et al. 2008, 894-907).
Nevertheless, the Transforming Growth Factor-β (TGFβ) family of
cytokines are the major and best characterized inducers of EMT, and are
associated with many biological processes such as the development of embryos,
wound healing, fibrotic diseases, and cancer progression (Ateeq et al. 2008, 266278;Massague 2008, 215-230;Yang and Weinberg 2008, 818-829). Recent
studies have shown involvement of TGF-β in regulating breast cancer stem cell
phenotypes (Mani et al. 2008, 704-715;Morel et al. 2008, e2888).
It is equally important to note that Hedgehog (HH) signaling has been
implicated in EMT, cancer metastasis, and regulates and maintains stem cell
characteristics in niche-stem cell interaction. The niche–stem cell interaction is
known to play an important role in triggering the EMT process (Bailey, Singh, and
Hollingsworth 2007, 829-839). Therefore Hedgehog (HH) signaling pathway is
becoming an important target in cancer therapy.

Epithelial to Mesenchymal Transition and Lung Cancer:
It is important to understand that invasion and metastatic processes vary
depending on the biological and anatomic characteristics of the primary organ.
For example, in non-small lung cancer (NSCLC) invasion is a complex process
due to the anatomy of the lung which lacks the anatomic support for invasion.
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Therefore, invasion in NSCLC is usually understood as cancer cells infiltrating
into their own newly formed desmoplastic stroma.
Desmoplastic stroma is a scar-like, highly fibrotic tissue that comprises
more than 50% of the tumor mass, and it differentiates to myofibroblast cells,
called Tumor Associated Fibroblast (TAF) (Bissell and Radisky 2001, 4654;Liotta 1986, 1-7). NSCLC progression from the adjacent desmoplastic stroma
is facilitated by the acquisition of the EMT phenotype by NSCLC cells. As
indicated earlier, the processes of EMT involves numerous changes in the levels,
distribution, and/or function of proteins including E-cadherins, vimentin,
fibronectin, matrix metalloproteinases and ZEB1/2 (Larue and Bellacosa 2005,
7443-7454). Importantly, in NSCLCs expression alterations of EMT-MET proteins
have been reported in both desmoplastic stroma and carcinoma cells (Kodama et
al. 2007, 269-274;Sasaki et al. 2001, 843-848).
Recent studies have employed gene expression, xenograft assays and
proteomic profiling techniques in order to find biomarkers associated with
sensitivity to erlotinib in panels of sensitive and insensitive NSCLC cell lines
(Thomson et al. 2005, 9455-9462;Witta et al. 2006, 944-950;Yauch et al. 2005,
8686-8698). Authors have found that sensitive cell lines express the wellestablished epithelial markers E-cadherin and catenin as well as exhibit the
typical cobblestone epithelial morphology and tight cell–cell junctions of epithelial
cells. On the other hand, insensitive cell lines did not have epithelial markers, but
they express protein characteristics of mesenchymal cells including vimentin,
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fibronectin and Zeb-1 consistent with more fibroblastic scattered morphology; this
trans-differentiation was found to be similar to cells undergoing the processes of
EMT. These observations were also extended to other cancer types including
pancreatic, colorectal (Buck et al. 2007, 532-541), head and neck (Frederick et
al. 2007, 1683-1691), bladder (Shrader et al. 2007, 277-285) and breast cancers
(Buck et al. 2007, 532-541) using EGFR antagonists.
Collectively, these results suggest that the processes of EMT may serve
as an indicator of sensitivity to EGFR inhibitors. Moreover, a study by Prudkin et
al has shown a clear association with these EMT markers in the sequential
pathogenesis of squamous cell carcinoma (Prudkin et al. 2009, 668-678),
suggesting that the combination of EGFR-TKI with the inhibitor of EMT-inducingmolecules could become a novel approach toward the treatment of lung cancer,
especially NSCLC, for which better innovative treatment is urgently needed.
It is well known that the expression levels of EGFR and/or mutated EGFR
are a predictor of the response to EGFR antagonists both in the clinic and in
cultured cell lines (Ono et al. 2004, 465-472;Thomson et al. 2005, 9455-9462). In
TRIBUTE, a NSCLC phase III randomized trial that compared a combination of
erlotinib and chemotherapy to chemotherapy alone, they showed provocative
findings

in

a

retrospective

analysis

of

E-cadherin

expression

immunohistochemistry in a subset of tumor specimens from patients.

by
The

authors found that tumors with strong E-cadherin staining had a drastically longer
time to progression (hazard ratio 0.37), without a significant increase in overall
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survival when treated with the combination of erlotinib and chemotherapy as
compared to chemotherapy alone, and these results were consistent with in vitro
findings (Gillan et al. 2002, 5358-5364;Yauch et al. 2005, 8686-8698). These in
vitro and clinical data indicate that the expression of E-cadherin or fibronectin,
and the quantification of EMT-phenotypic cells could be an excellent biomarker in
predicting the therapeutic response to EGFR inhibitors in NSCLC patients. These
results also suggest that the reversal of EMT to MET by novel approaches and/or
the sensitization of EMT-type cells with novel agents prior to treatment of NSCLC
with conventional chemotherapeutic agents or targeted agents would be
beneficial for the treatment of lung cancer. Hence, better understanding of the full
extent of the mechanisms of EMT as a crucial biological phenomenon in NSCLC
therapy is exetremely important.

Hedgehog (Hh) signaling pathway in Lung Cancer and Epithelial to
Mesenchymal Transition
The Hh signaling pathway is required for normal lung embryogenesis,
organogenesis, and is known to play important roles in stem cell maintenance. In
mammals, Hh ligands consist of three members: Sonic Hh (SHH), Indian Hh
(IHH), and Desert Hh (DHH). The hedgehog-ligands family consists of an Nterminal signal peptide, a Hedgehog core domain, and the C-terminal processing
domain. Hedgehog precursors are autocatalyzed to cleave the C-terminal
processing domain for cholesteroylation and are then further processed by
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Hedgehog acyltransferase (HHAT) to cut off the N-terminal signal peptide for
palmitoylation (Fig. 3). Mature Hedgehog proteins with lipid modifications are
then transported to the cell surface for packaging into lipoprotein particles
depending on Dispatched 1 (DISPl), or for multimerization via lipophilic tails.
Mature Hedgehog proteins secreted from producing cells induce concentration
dependent effects on target cells expressing Hedgehog receptor. PTCH1 and
PTCH2, Patched family members, are Hedgehog receptors distantly related to
Dispatch family members with multi-trans-membrane domains and a sterolsensing domain with PTCH1 acting as the predominant Hh receptor.
Smoothened is a seven trans-membrane type receptor which transduces Hhsignaling. CDON and BOC are trans-membrane proteins with extracellular
immunoglobulin-like (Ig-like), and fibronectin type III (FNIII) domains, which
enhance Hedgehog signaling activity as co-receptors. GASI is a GPI-anchored
cell surface protein binding to Hedgehog ligands for the potentiation of Hedgehog
signaling. On the other hand, HHIP is a negative regulator of Hedgehog
signaling, it compete with Patched receptors for Hedgehog-ligand binding (Fig.
4). GLI1/2 is a transcription factors functioning as a Hedgehog signaling
effectors. GLI1 gene initially cloned as an oncogene amplified in malignant
glioma, and then characterized as a transcription factor of Hh signaling pathway.
GLI1, GLI2, and GLI3 are human homologs of Drosophila Cubitus interruptus.
In the absence of Hh ligands, Patched family members inhibit
Smoothened function, GLI1 is transcriptionally repressed, GLI2 is phosphorylated

15

by GSK3 and CKI of the FBXWll (BTRCP2)-mediated degradation, and GLI3 is
processed to a cleaved repressor. Upon Hedgehog-ligand binding to PTCH1/2 is
rapidly internalized and consequently Smoothened is released from Patcheddependent suppression. Then Smoothened induces MAP3KlO (MST) activation
and SUFU inactivation for the stabilization and nuclear accumulation of GLI
family members, respectively. GLI1 functions as transcriptional activator of
Hedgehog target genes, while GLI2 and GLI3 function as transcriptional activator
or repressor in a context-dependent manner. Hedgehog signaling activation
leads to transcriptional activation of target genes through GLI-binding to the
GACCACCCA motif. GLI1, PTCH1/2 and HHlP1 are up-regulated by Hedgehog
signaling, while CDON, BOC and GASl are down-regulated. Hedgehogdependent GLl1 up-regulation constitutes a positive feedback loop, while
Hedgehog dependent regulation of PTCH1, HHlP1, CDON, BOC, and GASl
constitutes a negative feedback network. Hedgehog signals induce transient upregulation of target genes through the combination of positive and negative
feedback mechanisms. Hedgehog signals up-regulate CCNDl and CCND2 for
cell cycle acceleration, and similarly up-regulation of FOXA2, FOXC2, FOXE1,
FOXF1, FOXL1, FOXP3, POU3F1, RUNX2, SOX13, and TBX2 are known to be
important for cell fate determination. Hedgehog signals also up-regulate JAG2 to
regulate Notch, and lNHBC/I/E to regulate Activin signaling cascades. In addition,
Hedgehog signals up-regulate SFRPl at least in mesenchymal cells without its
promoter CpG hypermethylation to inhibit canonical WNT signaling cascade in
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epithelial cells (Fig.4) (Table 3.) (Krishnan et al. 1997, 1947-1950;Teh et al.
2002, 4773-4780;van Den Brink, de Santa, and Roberts 2001, 2115-2116).
Recently, the hedgehog (Hh) signaling pathway was reported to be active
in many cancers including NSCLC (Katoh and Katoh 2008, 271-275;Thayer et al.
2003, 851-856;Watkins et al. 2003, 313-317;Yuan et al. 2007, 1046-1055). In
addition, the Hh signaling blockade inhibits the growth, invasion and metastasis
of cancer cells having activated Hh signaling, which was associated with the
down-regulation of Snail and up-regulation of E-cadherin. Furthermore, overexpression of GLI-1 in epithelial cancer cells led to the aggressive phenotype
with down-regulation of E-cadherin (Feldmann et al. 2007, 2187-2196;Fukaya et
al. 2006, 14-29), suggesting that Hh signaling is an important regulator of EMT
and important target for therapy. Moreover, it has been reported that an EMT
regulator SIP1 is a target gene of the Hh signal in gastric pit cells and in diffusetype gastric cancer, and interestingly SIP1 regulates mesenchymal-related genes
(WNT5A, CDH2, PDGFRB, EDNRA, ROBO1, ROR2, and MEF2C) (Ohta et al.
2009, 389-398). In addition, it was found that Hh-signaling cascades cross-talk
with WNT, EGFR, FGF, and TGF-β/Activin/NodallBMP signaling cascades, all of
which have been implicated in EMT through the repression of E-cadherin
expression. Moreover, RTK signaling potentiates GLI activity through PI3K/AKTmTOR/P70S6K2-mediated GSK3β inactivation or RAS-STIL1-mediated SUFU
inactivation. Further evidence in support of the role of Hh signaling in EMT,
comes from recent studies showing that up-regulation of SNAl1 (Snail-1) and
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PTCH1 mRNAs was induced after GLI1 expression (Katoh and Katoh 2008, 271275) and that Hh signaling was found to be essential for the maintenance of
cancer stem cells (Zhao et al. 2009, 776-779). Collectively, all of these studies
clearly suggest that Hh signaling is a legitimate and novel target for the
development of innovative therapeutic strategies for the treatment of invasive
and metastatic cancer phenotypes with EMT or cancer stem-like cell
characteristics in NSCLC. In the list below (table 4.) different types of Hedgehog
pathway inhibitors, targeting different molecules in the Hh pathway are
presented. It is important to understand which model of Hh signaling applies to
each drug type because this has several implications for drug development and
therapy, for example, if cancer does not express Hh ligands, it will not respond to
Hh ligand blockers. Therefore, identification of Hh pathway elements and the
pathways for its cross-talks in patient’s tumor will provide a good predictive
marker of response.

Interaction and cross-talk between Nuclear Factor-Kappa B (NF-B),
Transforming Growth Factor-beta (TGF-), and Sonic hedgehog (Shh)
Hedgehog has been reported to cross-talk with NF-B, a major cell growth
and apoptotic regulatory pathway (Cui et al. 2010, 927-933;Kasperczyk et al.
2009, 21-33;Nakashima et al. 2006, 7041-7049;Umeda et al. 2010, 692698;Yamasaki et al. 2010, 675-686). NF-B plays important roles in the control of
cell growth, differentiation, apoptosis, and inflammation (Baud and Karin 2009,
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33-40;Campbell and Perkins 2006, 165-180;Grilli, Chiu, and Lenardo 1993, 162;Pikarsky and Ben-Neriah 2006, 779-784;Sethi, Sung, and Aggarwal 2008, 2131). NF-B is now known to induce and control a broad spectrum of genes
including inflammatory cytokines, chemokines, cell adhesion molecules, growth
factors, interferons, and viruses (Chen and Greene 2004, 392-401). NF-B
belongs to a family of proteins including members Rel A, c-Rel, Rel-B, Bcl-3,
p100 and p105. Under non-stimulated conditions, NF-B consists primarily of the
Rel A (p65) and p50 heterodimer associated with cytosolic IB inhibitory protein
(Vallabhapurapu and Karin 2009, 693-733). Following stimulation with an inducer
such as tumor necrosis factor α (TNF−α), Lipopolysaccharide (LPS) or H2O2,
NF-B is activated. The activation of NF-κB involves the phosphorylation of IB,
an inhibitory binding partner of NF-B complex, for ubiquitination and
degradation through the proteasome degradation pathway (Haefner 2005, 137188;Karin and Greten 2005, 749-759;Nakanishi and Toi 2005, 297-309). The free
NF-B complex is then translocated into the nucleus, binds to the DNA
consensus sequence and activates target genes (Chen et al. 2001, 16531657;Hacker and Karin 2006, re13). A key regulatory step in the NF-B pathway
is the activation of a high molecular weight IKK complex in which catalysis is
thought to be done by kinases, including IKKα and IKKβ, which directly
phosphorylate IB proteins (Chen et al. 2011, 1172-1185;Miyamoto 2011, 116130;Sun 2011, 71-85;Wajant and Scheurich 2011, 862-876). NF-B mediates
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survival signals that inhibit apoptosis and promote cancer cell growth (Chen et al.
2011, 1172-1185;Miyamoto 2011, 116-130;Sun 2011, 71-85;Sun 2011, 7185;Wajant and Scheurich 2011, 862-876;Zhao et al. 2011, 367-381). NF-B is
constitutively activated in most human lung cancer tissues and cell lines but not
in normal lung tissues and immortalized lung epithelial cells, suggesting that the
activation of NF-B is involved in the carcinogenesis of lung cancers (Chen et al.
2011, 1172-1185;Lin et al. 2010, 45-55;Saitoh et al. 2010, 263-270). It has been
shown that NF-B is activated in lung cancers through constitutive activation of
IB kinase (IKK) and degradation of IBα. Inhibition of NF-B by a super-inhibitor
of NF-B (delta-N-IBα) results in impaired proliferation and induction of
apoptosis, suggesting an important role of NF-B in lung cancer tumorigenesis
(Chen et al. 2011, 1172-1185;Lin et al. 2010, 45-55;Saitoh et al. 2010, 263-270).
Moreover, evidence has shown that NF-B participates in the process of lung
cancer metastasis (Chen et al. 2011, 933-941;Gupta et al. 2010, 405-434). Also,
number of K-Ras induced lung tumors are diminished, following the inactivation
of the NF-kappaB subunit p65/RelA, in the presence and the absence of the
tumor suppressor p53, suggesting that constitutive NF-B activity plays a key
role in lung cancer tumorigenesis and tumor progression (Basseres et al. 2010,
3537-3546;Meylan et al. 2009, 104-107). However, the precise molecular
mechanism by which NF-B is activated needs additional investigation.
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Particularly, TGF- is reported to induce the NF-B translocation to the
nuclei in activity-reporter assays (Arsura et al. 2003, 412-425;Gingery et al. 2008,
2725-2738;Yu et al. 2010, 869-878). Chow et al., found that TGF- suppresses
PTEN in pancreatic cancer cells through NF-B activation, and enhances cell
motility and invasiveness in a Smad4-independent manner that can be
counteracted when TGF--Smad2/3 signaling restored. Their data suggests that
the activation of NF-B is by Smad2 and/or Smad3, and not Smad-4 (Chow et al.
2010, G275-G282). Furthermore, TGF- ligand TGF-1 activates NF-B in
human osteoclast, and promotes osteoclast survival. Furthermore, TGF-1
transiently inhibits apoptosis in liver tumor through activation of NF-B (Arsura et
al. 2003, 412-425;Gingery et al. 2008, 2725-2738;Yu et al. 2010, 869-878),
suggesting that TGF-1 activates NF-B in cancer cells.
Interestingly, monocytes stimulated by Inflammation produced Shh
through activation of NF-B signaling pathway (Yamasaki et al. 2010, 675-686).
Also NF-B found to activate the hedgehog signaling pathway via induction of
Shh expression in pancreatic cancer specimens (Nakashima et al. 2006, 70417049). Also, it has been found that NF-B binds to Shh promoter regions prior to
the up-regulation of Shh expression. Authors have found that NF-B activation
results in increased Shh mRNA and protein expression in vitro and in vivo in an
inducible NF-B activity mouse model. Inhibition of NF-B by super-repressor
(inhibitory NF-B alpha; IB) or by p65 knock-down inhibits induction of Shh
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promoter activation and Shh expression by NF-B indicating that Shh expression
is regulated by NF-B and that NF-B-induced Shh involved in NF-B-mediated
proliferation and apoptosis resistance both in vitro and in vivo (Kasperczyk et al.
2009, 21-33).
TGF-, NF-B and Hh pathways are key regulators of numerous cellular
events such as proliferation, differentiation and apoptosis (Chen et al. 2011,
1172-1185;Inman 2011, 93-99;Massague 2008, 215-230;Zhao et al. 2009, 776779). TGF-and NF-B mediated cell growth and apoptotic resistance could in
part be mediated via up-regulation of Shh. Therefore, agents that inhibit Shh
signaling could be beneficial in the prevention or treatment of cancer.

Overall hypothesis
Lung is the leading cancer site in male, comprising 17% of the total new
cancer cases, and the most common cause of cancer related deaths with 23% of
the total cancer deaths. In the United States, The American Cancer Society
estimated that 222,520 Americans were diagnosed with lung cancer and 157,300
died of lung cancer in 2010 (Jemal et al. 2009, 225-249;Jemal et al. 2011, 6990).
Emerging evidence is accumulating suggesting that the phenomenon
called Epithelial-to-Mesenchymal Transition (EMT), which shares similar
molecular characteristics with cancer stem-like cells, contributes to lung cancer
treatment failure. EMT process has been implicated in the two important
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biological processes that are accountable for cancer-related deaths; the
progression of cancer cells to a distant organ and the acquisition of resistance to
conventional cancer therapeutics (Leng et al. 2011, 145-155;Shih and Yang
2011;Zhang et al. 2011). Therefore, further mechanistic understanding of the role
of EMT in lung cancer aggressiveness and treatment failure is very important.
Recently, studies have suggested that Hh signaling is an important
regulator of EMT and a crucial target for therapy. Among all major cancers
studies have shown that Hh signaling blockades inhibits the growth, invasion and
metastasis of cancer cells having activated Hh signaling which was associated
with the down-regulation of Snail and up-regulation of E-cadherin. Furthermore,
over-expression of GLI-1 in epithelial cancer cells leads to aggressive phenotype
with down-regulation of E-cadherin (Feldmann et al. 2007, 2187-2196;Fukaya et
al. 2006, 14-29),
Therefore, we hypothesize that the Hedgehog (Hh) signaling
pathway functions as a positive regulator of epithelial-to-mesenchymal
transition (EMT) in NSCLC; thus, it is an excellent target for lung cancer
therapy. We also hypothesize that Hh inhibitors sensitizes NSCLC cells to
cisplatin and/or EGFR-TKI by reversing the processes of EMT to MET.
We set out to test our hypotheses by accomplishing the following specific
aims.
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Specific Aims:

1. Examine the role of Hh signaling in the processes of EMT in vitro and in vivo,
especially because EMT has been shown to be associated with tumor
progression and cause resistance of non-small lung cancer (NSCLC) to
conventional therapeutics.

2. Assess the molecular mechanism of Hh signaling in the processes of EMT
and deregulation of miroRNAs (miRNAs).

3. Investigate whether down-regulation of Hh signaling could reverse EMT
phenotype and lead to the sensitization of NSCLC cells to conventional
therapeutics.
4. Investigate the expression of EMT markers (protein and mRNA) that are
involved in drug resistance of NSCLC cell lines before and after treatment
with Hh inhibitors.
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Table 1: Lung cancers major categories
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Table 2: Treatment Options for Lung Cancer
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Table 3. Downstream target genes of Hedgehog Signaling Pathway and
their functions
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Figure 1.
Morphologic hallmarks of epithelial and mesenchymal cells. Epithelial
morphology presented by an apical–basal polarity, joined with a basal basement
membrane and formation of extensive cell–cell contacts, including tight junctions.
While mesenchymal morphology featured by loss of anterior–posterior polarity, if
any, cell–cell junctions within a more unstructured interstitial matrix.
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Figure 2.
A simplified sketch of epithelial-to-mesenchymal transition regulating signaling
networks. Receptor tyrosine kinases (RTKs), transforming growth factor-β
(TGFβ), Notch, endothelin A receptor (ETAR), integrins, Wnt, hypoxia and matrix
etalloproteinases (MMPs) can induce EMTs through multiple different signaling
pathways, and the relative importance of each of these may depend on the
particular cellular context.
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Figure 3.
Hedgehog ligands family consist of N-terminal signal peptide, Hedgehog core
domain, and C-terminal processing domain. Hedgehog precursors are Autocatalyzed to cleavage the C-terminal processing domain for cholesteroylation,
and then further processed by Hedgehog acyltransferase (HHAT) to cut off the
N-terminal signal peptide for palmitoylation.
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Figure 4.
Illustration of Hedgehog Signaling Pathway in Cancer; Canonical and
noncanonical activation of Hedgehog pathway and it’s cross-talk among key
important signaling molecules.
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CHAPTER 2
MATERIALS AND METHODS

Cell culture and experimental reagents
The human lung adenocarcinoma cell lines, A549, H2030, H1299, H1650, and
mouse fibroblast NIH-3T3 cells were purchased from the American Type Culture
Collection (Manassas, VA) and maintained according to the American Type
Culture Collection’s instructions. The normal lung epithelial cell line (NHBE cells)
was purchased from Lonza. NHBE cells where maintained and cultured
according to Lonza’s instructions. All the cell lines have been tested and
authenticated using the Karmanos Cancer Center, Wayne State University core
facility (Applied Genomics Technology Center at Wayne State University) on
March 13, 2009, and these authenticated cells were frozen for subsequent use.
The method used for testing was short tandem repeat profiling using the
PowerPlex 16 System from Promega. A549 cells were treated with TGF-1 (5
ng/ml) for 21 days before experiments were conducted. Cells were treated with
GDC-0449 (20 nM) or Cyclopamine (2 mM) for 72 hours, before conducting
assays.

Reagents and antibodies
Anti-Shh N-terminal peptide antibody and recombinant human TGF-1 protein
was purchased from R&D Systems (Minneapolis, MN). Cyclopamine was
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purchased from Sigma (San Louis, MO) and diluted in dimethyl sulfoxide as a
control vehicle. GDC-0449 (20 nM) was obtained from Genentech. Rabbit antiGLI1 was purchased from Abcam. Rabbit anti-fibronectin was obtained from
Santa Cruz biotechnology (CA, USA). Antibodies to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) were purchased from Affinity BioReagents (Golden,
CO.). Mouse anti-bactin was obtained from Sigma (St. Louis, MO). -tubulin
rabbit mAb was obtained from cell signaling (Danvers, MA).

Plasmids, cloning and transfections
The Shh promoter plasmid encoding the Shh promoter region fused to RenSP
(optimized luciferase gene) reporter was purchased from switchgeargenomics.
Mutant shh-promoter-luciferase was generated by Site-Directed Mutagenesis kit
obtained from Oragene. The following primers were used: sence 5'- GGT GGG
GAG CGG TCG AGA GTC CGC CGC AGC CGC GGC -3', antisence 5'- GCC
GCG GCT GCG GCG GAC TCT CGA CCG CTC CCC ACC -3'. Afterward, Cells
were transfected with wild type Shh-promotor or mutant Shh-promoter,
respectively, using Fugene 6 transfection reagent (Roche). All plasmids were
controlled by sequencing.

Luciferase assays
Renilla luciferase activities determined using The Luciferase Reporter
Assay System (Promega) according to the manufacturer’s instructions. Using
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Fugene 6 Transfection Reagent (Roche), cells in 6-well plates were transfected
with Renilla luciferase vector under control of the ubiquitin promoter per well.
After 24 hrs, cells were stimulated as by TGF-1 for 24 hrs. Control cells were
not treated with TGF-1. Then cells were lysed with Passive Lysis Buffer
(Promega). The luminance of each well was measured in Ultra 26 Multifunctional
Microplate Reader (Tecan, Durham, NC). Results were plotted as means ± SD of
three separate experiments having three determinations per experiment for each
experimental condition.

Cell growth inhibition studies by MTT assay
Cells were seeded at (5 × 103) cells per 100 l of culture medium per well
in 96-well plates. The number of viable cells was assessed in six wells using a 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Sigma)
according to the manufacturer’s instructions, and then with isopropanol at room
temperature for 1 h. Cells were treated with Hh inhibitor (GDC-0449 or
Cycopamine) for 72 hour treatments, or knock-down with siRNA specific for Shh
(si-Shh) for 48 hours. Next, cells were treated for 72 hrs with either Cisplatin or
Erlotinib, at the concentration specified in the text. Control cells received 0.1%
DMSO or 0.5 mM Na2CO3 in culture medium. After treatment, the cells were
incubated with MTT reagent (0.5mg/ml; Sigma) at 37°C for 2 h and then with
isopropanol at room temperature for 1 h. Spectrophotometric absorbance of the
samples was determined by an Ultra-26 Multifunctional Microplate Reader
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(Tecan, Durham, NC). Results were plotted as means ± SD of three separate
experiments having six determinations per experiment for each experimental
condition.

Western blot analysis
Cells were lysed in lysis buffer (50 mM Tris, pH 7.5, 100 mM NaCl, 1 mM
EDTA, 0.5% NP-40, 0.5% Triton X-100, 2.5 mM sodium orthovanadate, 10 μl/ml
protease inhibitor cocktail and 1 mM PMSF) by incubating for 20 min at 4°C. The
protein concentration was determined using the Bio-Rad assay system (BioRad,
Hercules, Calif). Total proteins were fractionated using SDS-PAGE and
transferred onto nitrocellulose membrane. The membranes were blocked with
5% nonfat dried milk or BSA in 1 x TBS buffer containing 0.1% Tween 20 and
then incubated with appropriate primary antibodies. Horseradish peroxidase
conjugated anti-rabbit or anti-mouse IgG was used as the secondary antibody
and the protein bands were detected using the enhanced chemiluminesence
detection

system

(Amersham

Pharmacia

Biotech,

Piscataway,

NJ).

Quantification of Western blots was performed using ImageJ software and the
results are presented as the mean of three independent experiments with error
bars representing standard errors. For reprobing, membranes were incubated for
30 min at 50°C in buffer containing 2% SDS, 62.5 mM Tris (pH 6.7), and 100 mM
2-mercaptoethanol, washed and incubated with desired primary antibody.
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Real-time reverse transcription-PCR analysis for gene expression studies
Quantitative real-time RT-PCR analysis was conducted; 1 g of total RNA
from each sample was subjected to reverse transcription using the High-Capacity
RNA-to-cDNA Kit (Applied Biosystems) according to the manufacturer’s protocol.
Real-time PCR reactions were then carried out in a total volume of 25 l reaction
mixture (2 l cDNA, 12.5 l of 2 x SYBR Green PCR Master Mix from Applied
Biosystems, 1.5 l of each 5 mol/L forward and reverse primers, and 7.5 l
distilled H2O) using a SmartCycler II (Cepheid). The PCR program was started by
10 min at 950C before 40 thermal cycles, each at 15 s at 950C and 1 min at 600C.
Data were analyzed according to the comparative Ct method. Data was
normalized by glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression
in each sample. GLI1 primers have been previously described [25]. Shh primers
(Shh-forward:

GTGGCCGAGAAGACCCTA,

Shh-reverse:

CAAAGCGTTCAACTTGTCCTTA. GAPDH, ZEB1, and E-cadherin primers were
previously described (Kong et al. 2009, 1712-1721). Experiment was repeated at
least, three times independently. The primers were checked by running a virtual
PCR, and primer concentration was optimized to avoid primer dimer formation.
Also, dissociation curves were checked to avoid nonspecific amplification Data
reported here is one representative experiment
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Nuclear Extract Preparation
In brief, cells were washed with cold phosphate-buffered saline and
collected in conical centrifuge tubes. After a 5-min centrifugation, the pellet was
resuspended in a lysis buffer (100 mM HEPES, 100 mM NaCl, 1 mM EDTA, 1
mM EGTA, 1 mM DTT, 5 mM PMSF, 0.02 mg/ml leupeptin, 0.02 mg/ml aprotinin,
and 5 mg/ml benzamidine) and incubated on ice for 15 min. 12.5 μl of 10% NP40 for every 400 μl of cell suspension was added and the cells were lysed. The
disrupted cells were then centrifuged for 3 min at 20,000 x g at 4 °C, and the
supernatant was saved as a cytosolic extract. The pellet was resuspended in
extraction buffer (22.5 mM HEPES, 452 mM NaCl, 1 mM EDTA, 1 mM EGTA,
0.1 mM DTT, 0.1 mM PMSF, 0.2 g/ml leupeptin, 0.2 g/ml aprotinin, 0.05 mg/ml
benzamidine). The suspension was incubated on ice for 30 min with gentle
shaking and centrifuged at 20,000 x g for 5 min. The supernatant was stored as a
nuclear extract at –80°C. Nuclear protein (10 μg) was subjected to EMSA.

Electrophoretic mobility shift assay (EMSA) for measuring NF-B activity
A non-radioisotopic EMSA was used for measuring NF-B activity. NF-B
standard consensus double-stranded oligonucleotide and the Shh-promoter NFB binding region of wild-type and mutants double-stranded oligonucleotide was
5’ end-labeled with IRDye (IDT Integrated DNA Technologies), and used as a
probe, and the assays were performed in a final volume of 20 μl containing 20
mM HEPES, pH 7.9, 0.4 mM EDTA, pH 8, 0.4 mM DTT, 5% glycerol, 1% NP-40,
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60 mM NaCl, 2 μg poly (dI-dC), 10 μg nuclear extract, 2 pmol NF-B
oligonucleotide. The samples were incubated for 30 min at 37°C and were then
electrophoresed through 8% polyacrylamide gel, followed by scanning with The
Odyssey® Imaging System (LI-COR, Lincoln, NE). EMSA experiments were
done by additional 30 minutes incubations with polyclonal supershift antibodies
against p65 before the addition of labeled probe. Supershift assay using NF-B
p65 antibody was conducted to confirm the specificity of NF-B DNA-binding
activity. For loading control, 10 μg of nuclear proteins from each sample were
subjected to Western blot analysis for retinoblastoma protein, which showed no
difference in loading between samples. Images were scanned using laser
densitometry.

In vivo experiment
Four-week-old female ICR-SCID mice were obtained from Taconic
Laboratory (Germantown, NY). The mice were adapted to animal housing. Each
mouse received 1.5 x 106 A549 cells (control cells) and A549-M cells (in serumfree F-12) via tail-vein (Intravenous, IV) route. Mice were checked three times per
week for any sign of distress. Mice in the control and treated group were followed
for changes in body weight. Two Animals were sacrificed at four weeks, five
weeks, and finally three animals were sacrificed at six week following tumor cells
injection. Tumor tissues cut into two-halves, one-half was fixed in bouin’s
solution, and other half was formalin-fixed for histological staining with
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Hematoxylin and Eosin. Tumors foci were counted and pictures of tumor cells
taken under microscope at 4x magnification. Tumor foci count was plotted for
three animals, sacrificed at six weeks of each group. All studies involving mice
were done under Animal Investigation Committee–approved protocols.

Chromatin immunoprecipitation (ChIP) and Real-time polymerase chain
reaction (PCR) analysis
The ChIP assay kit (Upstate, Lake Placid, NY, USA) was used and the
assay was performed according to the manufacturer’s instructions, using rabbit
anti-p65 polyclonal antibody or IgG isotype as negative control antibody (Santa
Cruz Biotechnology) or mouse Anti-RNA polymerase II was used as positive
control for immunoprecipitation. Next, real-time PCR reactions were then carried
out in a total volume of 25 l reaction mixture (2 l DNA, 12.5 l of 2 x SYBR
Green PCR Master Mix from Applied Biosystems, 1.5 l of each 5 mol/L forward
and reverse primers, and 7.5 l distilled H2O) using a SmartCycler II (Cepheid).
the

following

primers:

5’-GAGCTCCACAAGCTCTCCAGGCTTGC-3’

and

antisense 5’-CTCGAGTCCTCGCTCCGGCTCGCCCGC-3’, previously Described
(Kasperczyk et al. 2009, 21-33). GAPDH primer was used as internal control and
the samples input were used as reference control.

Wound healing assay
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Cells were treated with TGF-1 for 21 days, Hh inhibitor for three-72 hour
treatments, or knock-down with siRNA specific for Shh (si-Shh) for 48 hours.
Prior to treatment, cells were seeded at 1x106 cells per well in a 6-well plates.
Upon 90% confluence, cells were scraped across the cell monolayer using a
plastic 200 l tip. Photomicrographs were taken with Phase contrast objective
microscope 4 x magnifications, at zero time point and after 24 hours. The
measured ratio of the remaining wound area relative to the initial wound area
was Quantified and reported. Quantification of the wound area using the NIH
Image-J program was performed, and the results are expressed as the
percentage of wound area change. Experiment was repeated at least three
times, independently. Data reported here is representative of an experiment.

Matrigel invasion assay
Cells were treated with TGF-1 for 21 days, Hh inhibitor for three-72 hour
treatments, or knock-down with siRNA specific for Shh (si-Shh) for 48 hours.
Following seeding cells at 5x104 cells/well, invading cells at the bottom of the
membrane and media in the lower chamber were detected by pre-labeled with
DiIC12 (3) Fluorescent Dye or by post-staining using immune-staining DiffQuickTM staining kit after removal of noninvasive cells. Cells were seeded in the
upper chamber of a 24-insert with serum-free medium. Upper chambers coated
with Matrigel (fluoro-block insert and MATRIGELTM Invasion Chamber; BD
Biosciences, USA). Lower chamber contained 10% FBS plus regular media.
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After 24 h of incubation, invading cells were examined by using a fluorescence
microscope and photographed. The transfection efficiency was photographed at
10X, whereas invading cells was photographed at 4X magnification. TECAN
Ultra imaging system was used to measure the fluorescence of invading cells.
Immunestained cells were also counted under phase contrast objective
microscope (10 X magnifications). The experiment was repeated at least three
times independently. Data reported here is one representative experiment.

Small interfering RNA (siRNA) transfection
Small interfering RNA (siRNA) specific for Shh (SHH Stealth RNAiTM
siRNA) was purchased from Invitrogen. As a nonspecific control siRNA,
scrambled siRNA duplex was used which was also purchased from Invitrogen.
Transfection was done using Lipofectamine RNAiMAX Transfection Reagent
(Invitrogen) following the manufacturer’s instruction. Shh was silenced by siRNA
in A549-M, H1650 and H1299 for 48 hrs prior to assay or treatment. Experiment
was repeated at least, three times independently. Data reported here is
representative of an experiment.

Clonogenic assay
Cells were treated with TGF-1 for 21 days, Hh inhibitor for three-72 hour
treatments, or knock-down with siRNA specific for Shh (si-Shh) for 48 hours.
Prior to treatment, cells were plated at a density of 1x103 cells in 100-mm Petri
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dishes. Then the cells were incubated for 10–14 days at 370C in a 5% CO2/5%
O2/90% N2 incubator. Next, colonies were stained with 2% crystal violet and
quantified using NIH Image-J software. The experiment was repeated at least
three times independently. Data reported here is representative of one
experiment.

microRNA (miRNA) Expression Profiling Microarray
Small RNA was isolated with the mirVana-miRNA Isolation Kit. Expression
levels of pooled miRNAs were measured by LC Sciences (Houston, TX, USA)
using miRHuman_10.0_070802 miRNA array chip, based on Sanger miRBase
Release 10.0

compared the miRNA expression of A549 samples to miRNA

expression data for A549-M. Preliminary statistical analysis was performed by LC
sciences on raw data normalized by Locally-weighted Regression (LOWESS)
method on the background-subtracted data. Then, Student’s t-test was
performed to identify the different miRNA expression. MiRNAs with P < 0.01 was
considered as having significant difference between.

Densitometric and statistical analysis
The optical densites of Smad and Psmad and GAPDH proteins on the films were
quantified and analyzed with ImageJ software (NIH).
The ratios of Smad and PSmad against GAPDH were calculated. The cell growth
inhibition by transfection or by GDC-09440 or Cyclopamine was statistically
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evaluated using ImageJ software (NIH). Comparisons were made between
control and transfection or treatment. The two-tailed v2 test was performed to
determine the significance of the difference among the covariates. P<0.05 was
used to indicate statistical significance.
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CHAPTER 3

Up-regulation of Sonic Hedgehog contributes to Epithelial to Mesenchymal
transition, and tumor progression of non-small lung cancer (NSCLC)
The work described in this chapter has been published
in the PloS ONE (2011), 6(1): e16068.

Lung cancer as the leading cancer site in male covers 17% of total new
cancer cases, and is the most common cause of cancer related deaths with 23%
of the total cancer deaths. As indicated earlier, The American Cancer Society
estimated that 222,520 Americans were diagnosed with lung cancer and 157,300
died of lung cancer in 2010 (Jemal et al. 2009, 225-249;Jemal et al. 2011, 6990). Epithelial-to-mesenchymal transition phenomenon plays critical role in tumor
invasion, metastatic dissemination and the acquisition of resistance to
conventional therapies and this phenotype in cancers has been associated with
poor clinical outcome in multiple cancer types including NSCLC (Baum,
Settleman, and Quinlan 2008, 294-308;Hugo et al. 2007, 374-383;Mani et al.
2008, 704-715;Morel et al. 2008, e2888;Sabbah et al. 2008, 123-151;Thiery and
Sleeman 2006, 131-142;Turley et al. 2008, 280-290). Interestingly, Hedgehog
(Hh) signaling pathway is an important mediator of carcinogenesis and cancer
metastases (Bailey, Singh, and Hollingsworth 2007, 829-839;Yoo et al. 2008,
480-490) and recent studies have shown that the acquisition of EMT phenotype
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is consistent with up-regulation of marker SNAl1 (Snail-1) and PTCH1 mRNAs,
and was induced after the induction of GLI1 expression (Katoh and Katoh 2008,
271-275). Moreover, Hh signaling was found to be essential for the maintenance
of cancer stem cells (Zhao et al. 2009, 776-779). This evidence supports the role
of Hh signaling in EMT and cancer metastasis. Inhibitors of the Hedgehog
signaling pathways have shown some early promise in preclinical and clinical
settings based on results showing that the inhibition of Hh signaling could inhibit
cell growth, invasion, and metastasis of cancer cells (Dolgin 2011, 523;Feldmann
et al. 2007, 2187-2196;Fukaya et al. 2006, 14-29;Ohta et al. 2009, 389-398).
Although epithelial-to-mesenchymal transition (EMT) phenomenon and
hedgehog signaling pathway have been demonstrated to result in tumor
metastases and invasiveness the exact role of Hh in EMT regulation in NSCLC
still undefined. To test my hypothesis whether Hh is a positive regulator of EMT
in NSCLC and whether Hh plays a role in EMT-induced tumor metastasis A549
and H2030 cells where exposted to TGF-1 cytokine, especially because TGF1 is the most well known inducer of EMT, for both two weeks and three weeks.
The chronic exposure was intended to recapitulate and mirror the in vivo
circumstance where tumor cells are exposed chronically to cytokines in patients.
Afterward, Hh signaling components expression were measured at mRNA and
protein levels in A549, H2030, H1650, and H1299 cell lines. Furthermore, EMT
markers were investigated in those cells, to confirm their EMT acquisition. In
addition, inhibition of Shh signaling was inhibited concomitant with TGF-
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treatment, to investigate whether Shh is required for the EMT induction. Next, I
investigated cellular assays such as invasion, migration, and tumorigenic ability
of these cells before and after Hh inhibition. Tumor invasiveness was also
measured in vivo.
Data showed for the first time that chronic exposure of A549 cells (NSCLC
cells) to TGF-1 lead to the acquisition of EMT phenotype concomitant with upregulation of sonic hedgehog (Shh) both at the mRNA and at the protein levels,
which was consistent with findings in another NSCLC cell line (H2030). The upregulation of sonic hedgehog was consistent with increased cell motility,
invasion, and tumor cell aggressiveness. Additionally, I found that this process
was attenuated by Shh siRNA as well as by Hh signaling inhibitors such as
cyclopamine and GDC-0449. Moreover, I found that the inhibition of Hh signaling
by pharmacological inhibitors led to the reversal of EMT phenotype, as confirmed
by the reduction of mesenchymal markers such as ZEB1 and Fibronectin, and
induction of epithelial marker E-cadherin. This data clearly suggested that the
acquisition of EMT phenotype by chronic exposue of NSCLC cells to TGF-1 is
mechanistically mediated by the activation of Shh signaling, especially because
the knockdown of Shh by Shh specific siRNA attenuated TGF-1-induced EMT
phenotype which establishs a mechanistic role of Shh with EMT.

Induction of epithelial-to-mesenchymal transition (EMT) in A549 NSCLC
cells by chronic exposure to TGF-1:
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It has been reported that A549 cells undergo EMT phenotypic changes
upon exposure to TGF-1 for 48-72 hrs (Kim et al. 2007, 898-904;Polyak and
Weinberg 2009, 265-273). In an attempt to recapitulate the in vivo situation
where cells are chronically exposed to TGF- 1 in the tumor microenvironment,
we exposed A549 cells to TGF- 1 for up to three weeks. After 21 days of
exposure to TGF- 1, A549 cell’s morphology was found to be completely
changed to a mesenchymal phenotype (we named these cells as A549-M cells),
with an elongated and disseminated appearance (Fig. 5A). I confirmed the
acquisition of mesenchymal phenotype by assessing EMT molecular markers
and ZEB1 mRNA, which was previously reported as a molecular marker of EMT
(Sanchez-Tillo et al. 2010, 3490-3500;Singh and Settleman 2010, 4741-4751),
and I found that ZEB1 was up-regulated while the expression of E-cadherin
mRNA, an epithelial marker, was down-regulated (Fig. 5B). Fibronectin protein, a
mesenchymal marker (Thomson et al. 2005, 9455-9462) was also found to be
highly up-regulated in A549-M cells (Fig. 5C) - all of which is consistent with the
acquisition of EMT phenotype.

A549-M cells showed significant increase in cell migration and invasive
characteristics compared to the A549 parental cells in vitro and in vivo:
Previous studies have shown that tumor cells with EMT phenotype aquire
invasiveness (Kim et al. 2007, 898-904;Singh and Settleman 2010, 47414751;Thomson et al. 2005, 9455-9462;Tsuji, Ibaragi, and Hu 2009, 7135-7139).
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To characterize A549-M cells a wound healing assay was performed. This
showed an increase in cell migration of A549-M cells compared to parental cells
(Fig. 6A). In addition, matrigel-coated chamber assay and clonogenic growth
assay showed that A549-M cells acquired more invasive and tumorigenic
characteristics compared to parental A549 cells (Fig. 6B, 6C). Furthermore, both
cell lines were injected through the tail vein of NOD/SCID mice where A549-M
cells showed enormous increase in the development of tumor foci compared to
A549 cells (Fig. 7) suggesting that EMT phenotypic cells acquired a
mesenchymal phenotype with increased cell motility and invasiveness both in
vitro and in vivo.

A549-M cells showed up-regulation of sonic hedgehog mRNA, and protein
expression:
Since Hh signaling has been implicated in EMT induction, metastasis and
invasion (Bailey, Singh, and Hollingsworth 2007, 829-839;Katoh and Katoh 2008,
271-275;Syn et al. 2009, 1478-1488;Watkins et al. 2003, 313-317;Yoo et al.
2008, 480-490;Yuan et al. 2007, 1046-1055) I sought to evaluate role of Hh
signaling pathway in TGF-1-induced EMT and characterize tumor cell
aggressiveness. Interestingly, there was a dramatic increase in the expression of
Hh pathway ligand Shh both at the mRNA and protein levels in A549-M cells
compared to parental A549 cells. Parental A549 cells showed undetectable
levels of Shh mRNA (Fig. 8A and Fig. 8B), consistent with previously published
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data (Sato, Leopold, and Crystal 1999, 855-864). Furthermore, I confirmed the
up-regulation of Shh by TGF- 1 treatment and the induction of EMT in another
NSCLC cell lines, H2030. H2030 cell line was treated with TGF- 1 for two
weeks, and I found a significant increase in the expression of Shh mRNA, which
was consistent with the induction of EMT marker ZEB1 and down-regulation of
epithelial marker E-cadherin (Fig. 9A). These results suggest that TGF- 1induced EMT is associated with transcriptional up-regulation of Shh. This novel
finding is the first such report in the literature. Surprisingly, GLI1 levels in both
A549-M and parental cells were higher compared to normal human bronchial
epithelial cells (NHBE cells) although the expression of GLI1 was much more
increased in A549-M cells (Fig. 8C and Fig. 8D). The high levels of Hh signaling
target gene GLI1 in both A549-M and A549 cells despite the undetectable levels
of Shh in A549 parental cells, implies that the expression of GLI1 could be ligand
independent in the parental A549 cells. Moreover, to investigate the possiblitiy of
GLI1 expression via autocrine or juxtacrine mechanisms, I cultured NIH-3T3
cells, mouse fibroblast cells, with conditioned medium collected from A549-M
cells or A549 parental cells. Data showed increased Hh signaling, which was
consistent with increased expression of GLI1 (Fig. 8E) in NIH-3T3 cells cultured
in the presence of conditioned medium collected from A549-M but not from the
parental A549 cells. These results suggest that A549-M cells secrete active Shh,
which is responsible for the activation of Hh signaling (activation of GLI1) in NIH
3T3 cells, resulting in the activation of GLI1.
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Shh up-regulation is required in EMT induction by TGF-1:
I further investigated the on the mechanism in which Shh up-regulation
mediates EMT induction after TGF-1 treatment. Knock-down of Shh by siRNA
significantly attenuated TGF-1 induced EMT as confirmed morphologically and
molecularly. The data is as follows: A549 cells transfected with Shh siRNA
(A549-siShh) 24 hrs prior to treatment with TGF-1 for 48 hours maintained
epithelial

morphology,

while

scrambled

siRNA

(A549-si-ve)

showed

transformation to mesenchymal morphology (Fig. 9B left panel) as expected.
Likewise, scrambled siRNA (A549-si-ve) showed more EMT induction following
re-transfection with Shh siRNA and treatment with TGF-1 compared to Shh
siRNA (A549-siShh) [Total six days of Shh siRNA transfection and five days of
TGF-1 treatment; please follow details under figure legend (Fig. 9B right panel].
The Shh siRNA trasfection resulted in a significant knock-down of Shh
expression as shown by qRT-PCR (Fig. 4C). These results are consistent with
significant attenuation in the induction of EMT markers subsequent to TGF-1
treatment. A549 cells with scrambled siRNA transfection showed downregulation of epithelial marker, E-cadherin and significant induction of ZEB1
expression, as expected (Fig. 9D, 48 hrs TGF-1), whereas TGF-1 failed to
show any effect on these markers in A549 with Shh knock-down (A549-siShh),
suggesting the mechanistic role of Shh in the induction of EMT induced by TGF-
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1. Moreover, further attenuation in the induction of EMT following second round
of Shh siRNA transfection and TGF-1 treatment was observed. A549-si-ve cells
showed a significant increase in ZEB1 expression consistent with significant
down-regulation of E-cadherin (Fig. 4D, 5 days TGF-1) whereas TGF-1 failed
to show any effect on these markers in scrambled A549-si Shh cells. These
results demonstrated for the first time that Shh up-regulation by TGF-1 is
required for TGF-1 induced EMT in NSCLC cells.

Up-regulation of Shh in A549-M cells contributes to EMT-induced tumor cell
migration and metastatic characteristics:
Next, I investigated the role of increased expression of Shh in the
aggressive behavior of tumor cells such as cell migration and metastatic potential
in A549-M cells. After treating A549-M cells with Smoothened inhibitors such as
cyclopamine or GDC-0449, A549-M cells showed significant reduction in cell
migration and invasion capacity (Fig. 10A–C and Fig. 14). To further confirm the
role of up-regulated Shh in A549-M cells after TGF-1 treatment, I assessed the
cells apptidtude for cell migration, invasion and tumorigenesis. We initially
assessed the transfection efficiency of cells after transfection with Shh-specific
siRNA, and we found high transfection efficiency (Fig. 11A) and were associated
with knock-down of Shh protein in these cells. The knock-down of Shh protein in
A549-M cells also demonstrated significant reduction in cell migration, invasion,
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and tumorigenic characteristics (Fig. 11B–D). These data further confirmed that
the inhibition in cell migration, invasion, and tumorigenic potential of A549-M cells
is mechanistically mediated through the inhibition of Shh autocrine signaling.

Down-regulation of Shh autocrine signaling in other NSCLC cell lines lead
to the reduction in tumor cell migration, invasion, and tumorigenic
characteristics:
I also further investigated the role of Shh autocrine signaling inhibition in
the reduction in cell migration, invasion, and tumorigenic potential in other
NSCLC cell lines that endogenously express Shh. For this purpose, I chose
H1299 and H1650 cell lines, both of which were derived from lung metastasis of
NSCLC patients. Both H1299 and H1650 cell lines showed resistance to
chemotherapy and targeted therapy, e.g. Erlotinib (Johansson et al. 2010, 383391;Teraishi et al. 2005, 6681-6687;Thomson et al. 2005, 9455-9462). Results
confirmed that both the cell lines expressed Shh as documented by qRT-PCR
and Western blot analysis (Fig. 12A). Treatment of both cell lines with Shh
inhibitors GDC-0449 or knock-down of Shh showed decrease in cell migration,
invasion and tumorigenic characteristics (Fig. 12B–C and Fig. 14, Fig. 13B-C and
Fig 15A-B). These results clearly provide strong experimental evidence in
support of the key-role of Shh in the induction of EMT phenotype associated with
tumor cell aggressiveness.
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Figure 5. Induction of epithelial to mesenchymal transition (EMT) in A549
cells by chronic exposure to TGF-1: TGF-1 was added to A549 cells in
culture media and maintained for 21 days with changing medium every third day
with freshly added TGF-1. A) Phase contrast microscopic pictures at 10X
magnifications. A549 cells morphology changed to mesenchymal phenotype
(A549-M cells). Cell shape appears elongated and non-polarized. B) qRT-PCR of
A549 and A549-M cells. A549-M cells showed lower expression of E-cadherin
‘‘epithelial marker,’’ and a higher expression of ZEB1 ‘‘EMT marker’’, at the
mRNA levels. Delta-delta-CT was calculated, considering GAPDH as internal
control and A549 parental as reference control. C) Western blot analysis where
A549-M cells showed up-regulation of fibronectin which is a ‘‘mesenchymal’’
marker compared to A549 parental cells.
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Figure 6. A549-M cells showed significant increase in cell migration,
invasive, and tumorigenic characteristics compared to A549 parental cells:
TGF-1-induced EMT phenotypic cells (A549-M cells) were generated as
discussed under ‘‘Materials and Methods’’ section. A: showed wound healing
assay results with its quantitative analysis. A549-M cells showed much higher
motility compared to A549 parental cells. B and C are showing the results of
matrigel-coated membrane and colony formation assays, respectively with its
quantitative analysis. Significant increase was observed in the invasion and
clonogenicity of A549-M cells compared to parental A549 cells. (* = p< 0.05).
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Figure 7. A549-M aquired remarkably increased invassivness in vivo: A549
and A549-M cell lines were injected through the tail vein of NOD/SCID mice,
tumors were harvested from the lung tissue. A549-M cells showed drastic
increase in the development of tumor foci compared to A549 cells. A, lung tissue
photographs after 6 weeks of tumor cell injection, top panel, tissue fixed with
bouin’s solution, bottom panel tissue crosssection stained with H&E. B, plot of
tumor foci count of H&E stained slides under microscope-4X, tumor foci count in
slides of three animals of each group after six weeks, and +/-SD represent the
error bars.
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Figure 8. A549-M cells showed up-regulation in the expression of sonic
hedgehog (Shh) and GLI expression both at the mRNA and protein levels:
A and B showing qRT-PCR and Western blot results, respectively for the
expression of Shh whereas C and D represent the expression status of GLI at
the mRNA and protein levels, respectively in A549-M cells compared to parental
A549 cells. E represent Western blot data of GLI1 expression in NIH-3T3 cell
after culturing them in the presence of conditioned medium collected from A549M cells showing higher levels of GLI1 expression. (* = p>0.05).
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Figure 9. Shh up-regulation was concomitant with TGF-1-induced EMT in
NSCLC cell lines. The up-regulation of Shh contributes to the EMT induction
through TGF-1. (A) H2030 cell line was treated with TGF-1 (5 ng/ml) for two
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weeks, and the media was changed every three days. The qRT-PCR data
showed induction in the expression of EMT marker ZEB1 mRNA, and reduced
expression of epithelial marker E-cadherin mRNA, which was consistent with upregulation of Shh mRNA similar to those observed in A549 cells exposed to TGF1. (B, C and D) A549 cells was transfected with Shh siRNA (A549-siShh) or
scrambled siRNA (A549-si-ve) for 24 hrs prior to treatment with TGF-1 (5
ng/ml) for 48 hrs, then the cells where collected for assays or re-transfected for
the second time with siRNA or scrambled siRNA for 24 hrs (total 6-days after
siShh transfection) prior to the second time treatment with TGF-1 (5 ng/ml) for
another 48 hrs (total 5-days of TGF-1 treatment). (B) Upper panel shows
transfection efficiency, and lower panel shows cellular morphology following
treatments. A549-siShh maintained epithelial morphology after treatment with
TGF-1 at both time points as shown in left and right panels, respectively. (C)
qRT-PCR expression of Shh mRNA showing significant down-regulation
following Shh siRNA transfection. (D) qRT-PCR expression of ZEB1 and Ecadherin mRNA. A549-si-ve cells showed down-regulation of epithelial marker,
E-cadherin consistent with significant induction in the expression of ZEB1 as
expected whereas TGF-1 failed to show any effect on these markers in A549siShh cells.
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Figure 10. Up-regulation of Shh in A549-M cells contributes to increased
tumor cells migration and metastatic characteristics: A549-M cells were
treated with Shh inhibitors such as Cyclopamine (2 mM) and GDC-0449 (20 nM)
and assayed for wound healing (A), invasion (B) and clonogenic growth (C), and
performed quantitative analysis showing attenuation of invasion by the treatment
of cells with Shh inhibitors.
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Figure 11. Reduction in A549-M cells motility, invasiveness, and
tumorigenesis by specific knock-down of Shh using Shh-specific siRNA:
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A549-M cells were transfected with Shh-specific siRNA (A): Transfection
efficiency as assessed by GFP. The effect of knock-down of Shh was assessed
by cell motility (wound healing) (B), invasion (C) and clonogenic growth (D) and
further quantitated as detailed under ‘‘Materials and Methods’’ section. The
results are showing a significant inhibition by Shh specific siRNA. (* = p>0.05).
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Figure 12. Down-regulation of Shh autocrine signaling in NSCLC cell lines
led to the reduction in tumor cell migration, invasion, and tumorigenesis: A;
both H1650 and H1299 cells expresses high levels of Shh mRNA compared to
NHBE cells, and both cell lines have high Shh protein expression. B and C
shows reduction in cell invasion and the colony-forming ability of H1650 cells
following treatment with Shh inhibitors such as GDC-0449 (20 nM).
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Figure 13. Down-regulation of Shh signaling in NSCLC cells lines (H1650
cells) led to reduced cell motility and invasion. (A): Transfection efficiency
was assessed by GFP. (B) Matrigel-Coated membrane assay where cells were
labeled with DiIC12 fluorescent dye. (C) Matrigel-Coated membrane assay where
cells were labeled with immune-staining kit (Quik staining kit). (B and C right
panel) also show quantitative data analysis. (*= p>0.05).
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Figure 14. Shh signaling inhibition decreases tumorigenic potential of
NSCLC cells: (A) clonogenic growth assay of three parental NSCLC cell lines
was compared to A549-M cells before and after treatment with Hh inhibitor GDC0449 (20 nM), and (B) represent quantitative data analysis of the data presented
in panel-A (* = p>0.05).
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Figure 15. Inactivation of Shh signaling by cyclopamine and GDC-0449 (20 nM)
led to the reduction in tumor cell invasion (A), and tumorigenic characteristics (B)
of H1299 NSCLC cell line. Right panel shows quantitative analysis. (* = p>0.05).
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CHAPTER 4

TGF-1 up-regulated sonic hedgehog in EMT-undergoing cells though
activation of NF-B, and microRNA (miRNA) machinery in NSCLC

As indicated earlier that lung is the leading cancer site in male covers 17%
of the total new cancer cases, and the most common cause of cancer related
deaths with 23% of the total cancer deaths. According to The American Cancer
Society estimates documenting that 222,520 Americans were diagnosed with
lung cancer and 157,300 died of lung cancer in 2010 (Jemal et al. 2009, 225249;Jemal et al. 2011, 69-90). The Epithelial-to- mesenchymal transition (EMT)
phenomenon plays a critical role in tumor invasion, metastatic dissemination and
the acquisition of resistance to conventional therapies, and the presence of EMT
phenotype in cancers has been associated with poor clinical outcome in multiple
cancer types including NSCLC (Baum, Settleman, and Quinlan 2008, 294308;Hugo et al. 2007, 374-383;Mani et al. 2008, 704-715;Morel et al. 2008,
e2888;Sabbah et al. 2008, 123-151;Thiery and Sleeman 2006, 131-142;Turley et
al. 2008, 280-290). Interestingly, Hedgehog (Hh) signaling pathway is an
important mediator of carcinogenesis and cancer metastases (Bailey, Singh, and
Hollingsworth 2007, 829-839;Yoo et al. 2008, 480-490), and transforming growth
factor-beta (TGF-β) is the most important inducer of EMT (Kalluri and Weinberg
2009, 1420-1428). We previously reported the up-regulation of sonic Hedgehog
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(Shh) following treatment with TGF-1 was a prerequisite for the induction of
EMT. However, the extact mechanism of TGF--Shh up-regulation is not clear.
Understanding of this process would therefore lead to specific therapeutic
treatments in a subset of NSCLC patients. Thus, I focused my investigation on
understanding the molecular mechanisms involving up-regulation of Shh gene
expression in NSCLC following TGF-1 treatment. I have characterized human
Shh promoter and its activation. Using combination of electrophoretic mobility
shift assay (EMSA), site-directed mutagenesis, luciferase reporter transient
transfection, and chromatin immunoprecipitation assays, I found the the
activation of NF-B in A549-M cells (A549 cells following treatment with TGF-β1),
which was consistent with increased expression of Shh. Furthermore, I
investigated the posttranscriptional regulation of Shh by microRNAs (miRNA),
well known negative regulators of gene expression at the posttranscriptional
level, which are involved in tumorigenesis (Cho 2007, 60;Krutovskikh and Herceg
2010, 894-904;Mocellin, Pasquali, and Pilati 2009, 70-80). To address this
question, I performed miRNA microarray using total RNA harvested from A549
and A549-M cells. Two miRNAs, miR-15a and miR-16, were found to be downregulated in A549-M cells compared to A549 cells. Both, miR-15a and miR-16
are located at chromosome 13q14, and have been implicated in cell cycle control
and apoptosis. Both are frequently deleted or down-regulated in squamous cell
carcinomas and adenocarcinomas of the lung (Bandi et al. 2009, 55535559;Palamarchuk et al. 2010, 3916-3922). Interestingly, in computational
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analysis of miRNA profiles and their targets, using UCSC, TargetScan and PITA
to predict potential target genes of miR15a and miR-16, Shh 3' untranslated
regions (3' UTRs) was identified as a target gene. This combination of miRNA
microarray and miRNA target gene data clearly show a consistent correlation
with up-regulation in the expression of Shh gene and down-regulation of miR-15a
and miR-16, suggesting that Shh up-regulation in A549-M is partly regulated by
miR-15a and miR-16. These findings could help in the development of new
therapeutic strategies that would allow re-expression of the lost miRNA such as
miR-15a and miR-16, suggesting that further in-depth research is warranted.

Identification of TGF-β1 downstream regulatory molecule:
TGF- has been reported to induce NF-B translocation to the nuclei in
activity-reporter assays (Arsura et al. 2003, 412-425;Gingery et al. 2008, 27252738;Yu et al. 2010, 869-878). Chow et al., found that TGF- suppresses PTEN
in pancreatic cancer cells through NF-B activation and enhances cell motility
and invasiveness in a Smad4-independent manner that can be counteracted
when TGF--Smad2/3 signaling is restored. These results suggest that the
activation of NF-B by Smad2 and/or Smad3, and not Smad-4 (Chow et al. 2010,
G275-G282). Furthermore, TGF- ligand TGF-1 activates NF-B in human
osteoclast, and promotes osteoclast survival. Furthermore, TGF-1 transiently
inhibits apoptosis in liver tumor through activation of NF-B (Arsura et al. 2003,
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412-425;Gingery et al. 2008, 2725-2738;Yu et al. 2010, 869-878), suggesting
that TGF-1 activates NF-B in cancer cells.
To investigate whether TGF-β1 chronic treatment activates NF-B in
A549-M cells, DNA-binding activity using an authentic NF-B–binding DNA was
assessed (Gupta et al. 2005, 125-143;Libermann and Baltimore 1990, 23272334) as shown in figure 16A. A549-M cells showed greater activation in the
DNA-binding activity of NF-B compared to parental A549 cells, suggesting the
induction of NF-B activity following TGF-1 treatment.

DNA-binding activity of NF-B in the consensus sites in the 5’ upstream
sequences in the Shh promoter:
It has been reported earlier that monocytes stimulated by inflammation
produce Shh through activation of NF-B signaling pathway (Yamasaki et al.
2010, 675-686). Moreover, in pancreatic cancer specimens, NF-B was found to
activate the hedgehog signaling pathway via induction of sonic hedgehog
expression (Nakashima et al. 2006, 7041-7049), and it was further shown that
NF-B binds to Shh promoter regions prior to the up-regulation of Shh
expression. These authors have found that NF-B activation results in increased
Shh mRNA and protein expression in vitro, and in vivo in an inducible NF-B
activity mouse model. Inhibition of NF-B by super-repressor (inhibitory NFBalpha; IB) or by p65 knock-down showed inhibition in the induction of Shh
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promoter activation and Shh expression, suggesting that Shh expression is
regulated by NF-B, and that NF-B-induced Shh is involved in the NF-Bmediated cells proliferation and resistance to apoptosis, both in vitro and in vivo.
In addition, the NF-B binding site at position +139 is required for NF-Bmediated up-regulation of Shh transcriptional activity (Fig. 16B) (Kasperczyk et
al. 2009, 21-33). To investigate whether NF-B binds to 5’ upstream region in the
Shh promoter, nuclear extracts obtained from A549 or A549-M cells were mixed
with infrared-labeled oligonucleotides specific for the concensus NF-B binding
site (Fig. 16B), or the mutated oligonucleotide, and the resulting NF-B binding
complexes were resolved through EMSA. Interestingly, putative NF-B binding
sites within the human Shh promoter region formed NF-B complexes, and
further showed that NF-B complexes have the lowest binding activity to mutant
three (MUT-3) of Shh promoter region (Fig. 13A). To examine the specificity of
NF-B DNA binding complexes, I performed EMSA supershift experiments.
Antibodies recognizing p65 subunits caused a significant supershift of NF-B
DNA binding complexes using authentic NF-B oligonucleotide bound to the Shh
promoter (Fig.17B).
Next, I performed ChIP experiments using nuclear extracts from A549
cells in order to investigate whether NF-B binds to the Shh promoter in vivo
following TGF-1 treatment, using an antibody to p65 subunit of NF-B. TGF-1
stimulated NF-B activation in A549 cells resulted in increased binding of p65 to
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the Shh promoter region (Fig. 18). Together, this set of experimental data clearly
suggests that NF-B binds to the Shh promoter following treatment with TGF-1
resulting in the induction of Shh expression. This is more direct evidence
establishing the the role of NF-B in the activation of Shh during TGF-1-induced
acquisition of EMT phenotype in NSCLC cells compared to the loss of miR-15a
and miR-16 which also contributes to the induction of EMT.

Transcriptional activation of the Shh promoter by NF-B:
Next, to address the question whether NF-B transcriptionally activates
the Shh promoter, a 5000-bp fragment of DNA that contains the human Shh
promoter and 5’ upstream region with the +139 putative NF-B binding sites, was
fused to upstream Renilla luciferase gene. This construct was obtained from
Switchgear genomics. I employed site-directed mutagenesis to generate mutants
in the putative NF-B binding region, with the same mutation as mutant three of
the oligonucleotide experiment as presented Fig. 17. Next, A549 cells were
transfected with wild type Shh promoter-luciferase plasmid or the mutant Shh
promoter-luciferase plasmid and subsequently treated with TGF-1, while control
cells were transfected with wild type Shh promoter-luciferase without TGF-1
stimulation. Luciferase enzyme activity was measured; A549 cells treateted with
TGF-1 after they were transfected with wild type Shh promoter (Shh+TGF-1)
showed a four fold increase in luciferase activity compared to control, while A549
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cells with mutant construct had an insignificant increase in luciferase activity (Fig.
19). This suggested that NF-B transcriptionally activates Shh promoter following
treatment with TGF-1 in NSCLC.

Constitutive phosphorylation of Smad2 following chronic stimulation with
TGF-1:
Chow et al. group reported that in pancreatic cancer cells TGF-1 activate
NF-B and enhances cell motility and invasiveness in a Smad4-independent
manner which can be cancelled out when TGF--Smad2/3 signaling restored.
Their data suggests that the activation of NF-B is by Smad2 and/or Smad3, and
not Smad-4 (Chow et al. 2010, G275-G282). Therefore, I investigated the
involvement of NF-B upstream molecule, Smad2, in TGF-1 stimulation of NFB activity prior to Shh up-regulation. The Smad phosphorylation kinetics in TGF1-stimulated A549 cells shows highest levels of phospho-Smad (pSmad)
expression after five hours of treatment, and after 24 hours pSmad dropped
down to its basal levels (Fig. 20). Interestingly, A549-M cells had constitutive
phosphorylation of Smad, even after TGF-1 discontinuation. These results
suggests that Smad, as downstream signaling molecule of TGF-1, may be
involved initially in the activation of NF-B, consistant with previous reports
(Chow et al. 2010, G275-G282) and subsequent induction of Shh in EMT
phenotypic cells, and that there is a feedback mechanism that kept sustained
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activation of Smad2 in A549-M cells. Interestingly, it has been reported that
phosphorylation of Smad 3 was enhanced by treatment with N-Shh (Yoo et al.
2008, 480-490); however, further in-depth research is warranted.

Shh is a possible target gene of miRNA-15a and miRNA-16:
Further

investigation

was

focused

on

miRNAs

because

the

posttranscriptional regulation of Shh by miRNAs could play an important
regulatory role. miRNAs are especially known to function as negative regulators
of gene expression at the posttranscriptional level and are critically involved in
tumorigenesis (Cho 2007, 60;Krutovskikh and Herceg 2010, 894-904;Mocellin,
Pasquali, and Pilati 2009, 70-80). As previously indicated I performed miRNA
microarray using total RNA extracted from A549 and A549-M cells. Two miRNAs,
miR-15a and miR-16, were found to be down-regulated in A549-M cells
compared to A549 cells. Both miR-15a and miR-16 are located at chromosome
13q14 and have been implicated in cell cycle control and apoptosis. Both
miRNAs are frequently deleted or down-regulated in squamous cell carcinomas
and adenocarcinomas of the lung (Bandi et al. 2009, 5553-5559;Palamarchuk et
al. 2010, 3916-3922). Interestingly, computational analysis of miRNA profiles and
their targets, using UCSC, TargetScan and PITA to predict potential target genes
of miR15a and miR-16 what that the Shh 3' untranslated regions (3' UTRs) were
their potential target (Fig. 21). A Combination of miRNA microarray data and
miRNA target genes data correlates with Shh gene up-regulation, suggesting that
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Shh up-regulation in A549-M can be partly due to the loss of miR-15a and miR16 expression.
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A

B

A549-M

A549

NF-B

Figure 16. Increaced activation of NF-B following chronic treatment with
TGF-1: (A), A549-M cells have greater activation in NF-B compared to A549
cells as assessed by electrophoretic mobility shift assay (EMSA) (B) Promoter
and 5’ upstream region of the human Shh gene, Nucleotide sequence of the
human Shh promoter. Arrows correspond to the two transcriptional start sites,
TSS 1 and TSS 2. TATA and CCAAT boxes, and putative sites for transcription
factors binding, are indicated by boxes. Positions were counted relative to the
first TSS (Figure 12B. courtesy of Kasperczyk group).
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Figure 17. NF-B complexes bound to NF-B binding site within the human
Shh promoter region. (A), putative NF-B binding site within the human Shh
promoter region bound NF-B complexes, and NF-B complexes showed the
lowest binding activity to mutant three of Shh promoter region, in A549 and
A549-M cells (B), Antibodies recognizing p65 subunits caused a significant
supershift of NF-B DNA binding complexes documenting the specificity of the
complex.
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A549 plus TGF-1, CHIP assay

Figure 18. NF-B binds to the Shh promoter following treatment with TGF1. Using an antibody to p65 subunit of NF-B, TGF-1 treatment showed
stimulation in the NF-B activation in A549 cells, resulting in increased binding of
p65 to the Shh promoter region.
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A549 after 24hrs treatment with TGF-1

Figure 19. NF-B transcriptionally activates Shh promoter following
treatment with TGF-1 in NSCLC cells. A549 cell were transfected with wild
type Shh promoter-luciferase plasmid or the mutant Shh promoter-luciferase
plasmid and subsequently treated with TGF-1, while control cells was
transfected with wild type Shh promoter-luciferase, without TGF-1 treatment.
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Figure 20. Constitutive phosphorylation of Smad2 following chronic
treatment with TGF-1. (A) Smad phosphorylation Kinetics in TGF-1-treated
A549 cells showing highest levels of phospho-Smad (pSmad) expression after
five hrs of treatment; however, after 24 hrs pSmad levels drop-down to basal
levels. (B), A549-M cell had constitutive phosphorylation of Smad, even after
TGF-1 treatment discontinuation.
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Shh 3’ UTR 5’ TGCTGGCGAGATGTCTGCTGCTAGTCCTCGTCTCCTCGCTGCTGGTATGCTCG

||||||||

hsa-miR-15a 3’GUGUUUGGUAAUACACGACGAU
hsa-miR-16a 3’CGGUUAUAAAUGCACGACGAU

Figure 21. Shh is a possible target gene of miRNA-15a and miRNA-16. using
UCSC, TargetScan and PITA to predict potential target genes of miR15a and
miR-16, Shh 3' untranslated regions (3' UTRs) was identified as a potential
target, suggesting that Shh gene is regulated through miR-15a and miR-16.
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CHAPTER 5

Hedgehog inhibitors sensitizes EMT-phynotypic cells to conventional
therapeutics in NSCLC cells
Lung cancer causes the highest mortality rate among cancers and also
results in short survival rate because most of the patients are in later stages and
have a high incidence of metastatic disease at the time of diagnosis which lacks
effective therapy. The standard therapeutic approaches of advanced disease
have failed miserably in this case (Herbst et al. 2011, 1846-1854;Jemal et al.
2008, 71-96;Jemal et al. 2009, 225-249;Jemal et al. 2011, 69-90). Recent studies
employed gene expression, xenograft assays and proteomic profiling techniques
to find biomarkers associated with sensitivity to erlotinib in panels of sensitive
and insensitive NSCLC cell lines (Thomson et al. 2005, 9455-9462;Witta et al.
2006, 944-950;Yauch et al. 2005, 8686-8698). These authors have found that
sensitive cell lines express the well-established epithelial markers E-cadherin
and catenin as well as exhibit the typical cobblestone epithelial morphology and
tight cell–cell junctions of epithelial cells. On the other hand, insensitive cell lines
did not have epithelial markers and they express protein characteristics of
mesenchymal cells, including vimentin, fibronectin, and Zeb-1 consistent with
more fibroblastic scattered morphology; this trans-differentiation is similar to cells
undergoing the processes of EMT. Collectively, these results suggest that the
processes of EMT may serve as an indicator of sensitivity to EGFR inhibitors.

81

Moreover, a study by Prudkin et al. has shown a clear association with these
EMT markers in the sequential pathogenesis of squamous cell carcinoma
(Prudkin et al. 2009, 668-678), suggesting that the combination of EGFR-TKI
with the inhibitor of EMT-inducing-molecules could become a novel approach
toward the treatment of lung cancer, especially NSCLC.
Recently, the hedgehog (Hh) signaling pathway was reported to be active
in many cancers including NSCLC (Katoh and Katoh 2008, 271-275;Thayer et al.
2003, 851-856;Watkins et al. 2003, 313-317;Yuan et al. 2007, 1046-1055). In
addition, the Hh signaling blockade inhibits the growth, invasion and metastasis
of cancer cells having activated Hh signaling, which was associated with the
down-regulation of Snail and up-regulation of E-cadherin. Furthermore, overexpression of GLI1 in epithelial cancer cells led to aggressive phenotype with
down-regulation of E-cadherin (Feldmann et al. 2007, 2187-2196;Fukaya et al.
2006, 14-29) suggesting that Hh signaling is an important regulator of EMT and
important target for therapy. Moreover, Hh signaling was found to be essential for
the maintenance of cancer stem cells (Zhao et al. 2009, 776-779). Collectively,
all of these studies clearly suggest that Hh signaling is a legitimate and novel
target for the development of innovative therapeutic strategies for sensitization of
invasive and metastatic cancer with EMT or cancer stem-like cell characteristics
to standard therapies in NSCLC.
To address this question, A549-M and H1299, mesenchymal phenotypic
cell lines, were treated by Hh inhibitor GDC-0449 (table. 4) for three days. Next,
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cells were treateted with cisplatin (Cis) or Erlotinib (Erlo), the epidermal growth
factor receptor-tyrosine kinase inhibitor (EGFR-TKI), and then cell viability was
assessed. Furthermore, Shh was knocked-down by siRNA in A549-M or H1299
cells and then treated with Cis or Erlo, and cell viability was determined with the
change in the half-maximal inhibitory concentration (IC50). The data showed a
significant decrease in IC50 for both Cis and Erlo, suggesting that Hh inhibitor can
sensitize resistant NSCLC cell lines with mesenchymal phenotype to standard
therapies.

A549-M cells with mesenchymal phenotype showed more resistance to
cisplatin and EGFR-TKI (erlotinib) compared to A549 cells:
Epithelial-to-mesenchymal transition (EMT) phenotypic cancer cells have
been shown to acquire drug resistance (Bao et al. 2011;Gomes et al. 2011;Hotz,
Hotz, and Buhr 2011, 448-454;Nicolini et al. 2011, 1486-1499). Our data showed
that A549 with mesenchymal phenotype (A549-M) acquire invasiveness in vitro
as will as in vivo (Maitah et al. 2011, e16068), and thus I investigated whether
A549 cells with mesenchymal phenotype (A549-M) has indeed acquired the drug
resistance

phenotype

associated

with

the

acquisition

of

mesenchymal

phenotype. A549 or A549-M cells were treated with cisplatin or erlotinib, and then
measured cell viability by colorimetric assays (MTT). A549-M indeed showed
greater viability compared to A549 cells, suggesting that A549-M cells are more
resistant to cisplatin or erlotinib, consistent with the EMT phenotype (Figure. 22).
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Hedgehog inhibitor GDC-0449 sensitizes mesenchymal phenotypic cells to
cisplatin and EGFR-TKI (erlotinib):
Next, I evaluated whether Hedgehog inhibitor GDC-0449, can sensitize
A549-M cells to cisplatin or erlotinib, and thus A549-M cells were treated with
GDC-0449 (GDC) for three days, subsequently these cells where treated with
cisplatin or erlotinib at different concentration, and the cell viability was assessed
after 72 hrs of treatment. A549-M cells treated with GDC showed less cell
viability (Table. 4), suggesting that Hh inhibitor GDC sensitizes mesenchymal
phenotype cells to standard therapy. In our previous data TGF-1 up-regulated
Shh, and Shh was required to induce EMT by TGF-1, and also found that the
inhibition of Shh abrogated A549-M cell’s migration and invasion ability.
Therefore to further confirm the role of TGF-1-induced up-regulation of Shh,
Shh was inhibited by knock-down and tested whether the knock-down of Shh will
sensitize A549-M cells siliar to treatment with GDC. A549-M cells were
transfected with Shh specific siRNA, control cells were transfected with
scrambeled siRNA, then the cells were treated with cisplatin or erlotinib. A549-M
cells with Shh knock-down showed significant reduction in cell viability (Fig. 23).
These data clearly suggests that Hh inhibition is a good therapeutic strategy to
sensitize drug resistant cells with EMT phenotype to standard therapy.
Next, for confirming this conclusion, another NSCLC cell line with
mesenchymal phenotype was used. H1299 cells reported to have mesenchymal
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phenotype with resistance characterestics to cisplatin and erlotinib (Ceppi et al.
2010, 1207-1216;Takeyama et al. 2010, 216-224;Thomson et al. 2005, 94559462). Thus, H1299 cells were treated with GDC for 72 hrs prior to treatments
with cisplatin or erlotinib whereas control cells were treated with cisplatin or
erlotinib only, and after 72hrs of cisplatin or erlotinib treatments, the cellular
viability were determined. H1299 cells treated with GDC showed lesser cell
viability compared to H1299 cells untreated with GDC, and these results are
consistent with the results obtained from A549-M cells (Fig. 24). I also confirmed
the specific role of the ligand Shh in H1299 cells in drug-sensitivity after
treatment with hedgehog inhibitor (GDC) and by using Shh siRNA knock-down
prior to treatment with cisplatin or erlotinib. H1299 cells with Shh knock-down
showed decreased cell viability, confirming the involvement of Shh in restoring
sensitivity to standard therapy. Together, these results suggests that treatment of
patients with hedgehog inhibitor prior to or concurrent with standard therapy
could improve therapeutic outcome in patients whose tumor show EMT features.

Hedgehog inhibitor down-regulates epithelial to mesenchymal marker in
non-small lung cancer cells:
In order to gain further insight on reversing drug sensitivity to
conventional therapeutics by hedgehog inhibitor, further experiments were
conducted. Hedgehog signaling pathway has been implicated in EMT regulation
(Chen et al. 2011;Choi et al. 2010, 36551-36560;Maitah et al. 2011,
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e16068;Omenetti et al. 2011, 1246-1258;Sarkar et al. 2010, 383-394;Takebe,
Warren, and Ivy 2011, 211;Zheng et al. 2010, 965-970). Also, inhibition of
hedgehog pathway showed down-regulation of EMT markers (Feldmann et al.
2007, 2187-2196;Merchant and Matsui 2010, 3130-3140;Xu, Ma, and Wang
2009, 119-124). I evaluated whether hedgehog inhibitor could down-regulate
EMT markers in NSCLC cells, A549-M, H1299 and H1650 cells where treated
with GDC, then EMT markers fibronectin and ZEB1 were examined together with
assessment of epithelial marker E-cadherin. Data showed that mesenchymal
markers fibronectin and ZEB1 were down-regulated after treatment with GDC
whereas epithelial marker E-cadherin was up-regulated (Fig. 25), suggesting that
the reversal of drug resistance is in part mediated through the reversal of EMT
phenotype. Together, these data clearly suggest that hedgehog inhibitor will
restore drug sensitivity by reversing the EMT phenotype, and thus Hh inhibitor
may play a critical role in sensitizing EMT phenotypic NSCLC cells to standard
therapies.
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Figure 22. A549-M cells acquired drug resistance phenotype: Left panel,
A549-M cells showed greater cell viability, after treatment with erlotinib compared
to A549 cells. Right panel A549-M cells showed greater cell viability, after
treatment with cisplatin compared to A549 cells.
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A

B

Figure 23. Knock-down of Shh sensitizes A549-M cells to standard
therapies: (A) Reduction in cell viability of A549-M cells treated with erlotinib
following Shh knock-down, (B) A549-M treated with cisplatin following Shh
knock-down showed reduced cell viability.
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A

B

Figure 24. Hedgehog inhibitor (GDC) sensitizes H1299 cells to standard
therapies: (A) Reduction in cell viability of H1299 cells treated with erlotinib
following Hedgehog inhibitor (GDC), (B) H1299 treated with cisplatin following
Hedgehog inhibitor (GDC) showed reduced cell viability.
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A

A549-M

C

B

D
H1299

Figure 25. Hedgehog inhibitor down-regulates epithelial to mesenchymal
marker in NSCLC: (A, C) western blot showing reduction in the expression of
fibronectin, a mesenchymal marker, following treatment with Hedgehog inhibitor
(GDC) in both A549-M and H1299 cells; (B, D) qRT-PCR showed downregulation in the EMT marker ZEB1, and up-regulation of epithelial marker Ecadherin after treatment with Hedgehog inhibitor (GDC) in both A549-M and
H1299 cells.
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IC50 (M)

% decrease in
IC50 with GDC
treatment

Cell line

Standard
therapy

A459-M

Erlotinib

43.64

15.76

63.89

Cisplatin

36.16

9.641

73.34

Erlotinib

10.57

7.198

31.90

Cisplatin

12.15

4.185

65.56

H1299

Without
GDC

With
GDC

Tabel 4. Treatment of NSCLC cells with hedgehog inhibitor showed
significant decrease the half-maximal inhibitory concentration (IC50) of both
erlotinib and cisplatin: The table shows changes in the IC50 of erlotinib and
cisplatin with and without prior treatment with GDC; last column on the right
shows the persantage decrease in the IC50 following GDC, in both A549-M and
H1299 cells.
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CHAPTER 6

Discussion
Previous studies have shown that the treatment of NSCLC cells (A549
cells) with TGF-1 could induce EMT phenotype (Kasai et al. 2005, 56;Kim et al.
2007, 898-904;Saitoh et al. 2010, 263-270). EMT is a process that was originally
reported to be involved in embryogenesis and gastrulation (Gunhaga, Jessell,
and Edlund 2000, 3283-3293;Kang and Massague 2004, 277-279;Thiery 2003,
740-746;Thiery and Sleeman 2006, 131-142). The induction of EMT in cancer
cells confers these cells with the ability to become more motile and invasive with
increased tumorigenic potential (Kang and Massague 2004, 277-279;Larue and
Bellacosa 2005, 7443-7454;Singh and Settleman 2010, 4741-4751;Thiery and
Sleeman 2006, 131-142;Thomson et al. 2005, 9455-9462;Tsuji, Ibaragi, and Hu
2009, 7135-7139;Yauch et al. 2005, 8686-8698). Furthermore, the EMT
phenotype appears to be involved in resistance to conventional therapeutics.
Thus, reversal of EMT by novel approaches may provide a tool by which one
could enhance the effects of conventional therapeutics with better treatment
outcome in NSCLC patients.
In this study, NSCLC cell lines (A549 and H2030) with EMT phenotypic
changes (A549-M and H2030-M cells) after chronic exposure to TGF-1 was
employed, which showed consistent results with decreased expression of
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epithelial markers concomitant with increased expression of mesenchymal
markers (Fig. 5A–C; Fig. 9A). To investigate the aggressivness of A549-M cells, I
assessed the ability of A549-M cells compared to A549 parental cells for cell
migration, invasion and tumorigenic potential in vitro as will as in vivo. Our data
showed increased ability of A549-M cells for cell migration, invasion and
tumorigenic potential compared to parental A549 cells (Fig. 6A–C, and Fig. 7).
Interestingly, we also found that A549-M and H2030 cells showed high
expression of Shh both at the mRNA and protein levels compared to parental
cells (undetectable levels of Shh expression) (Fig. 8A–B; Fig. 9A). The upregulation of Shh expression in A549-M cells is the first such report. Shh upregulation was also consistent with increased expression of GLI1 transcription
factor, a downstream target gene of Hh signaling pathway (Fig. 8C–D) although
the basal level of GLI1 expression was found to be high in the parental A549
cells, suggesting that Hh signaling could be active through noncanonical pathway
(ligand-independence) in these cells. This novel finding is very interesting,
because it connects two very important molecules in the developmental pathway,
TGF-1 and Shh, with tumor aggressiveness (Bethea et al. 2009, 94-108;Hogan
1999, 225-233). Also this finding is consistent with published reports showing the
role of EMT in tumor aggressiveness and metastasis (Katoh and Katoh 2008,
271-275;Sanchez-Tillo et al. 2010, 3490-3500;Thayer et al. 2003, 851-856;Zhao
et al. 2009, 776-779). However, no studies have shown direct up-regulation of Hh
ligand Shh mRNA and protein by TGF-1 as documented in this report although
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Shh has been reported to activate TGF- family signaling through the ALK5Smad 3 pathway in gastric cancer cells (Yoo et al. 2008, 480-490). Moreover, it
has been reported that TGF-1 can induce GLI2 activation through Smad3 in
pancreatic adenocarcinoma cell lines (Dennler et al. 2007, 6981-6986), and
these results suggest that there may be a feedback loop connecting TGF-1 with
Shh activation. Our finding also suggest that Hh signaling pathway reactivation in
cancer epithelial cells within the tumor microenvironment could lead to the
acquisition of aggressive phenotype of cancer cells within a tumor. Also, our data
clearly suggest that the up-regulation of Shh by TGF-1 leads to increased tumor
cell migration, invasion and tumorigenic potential of A549-M cells as documented
by our mechanistic experiments using knock-down approach and by using
inhibitors of Hh-signaling pathway (Fig. 10 and Fig. 11).
Our results also suggest that the maintenance of EMT phenotype in A549M cells may be related to the sustained activation of Hh. These results are also
consistent with two other NSCLC cell lines that were derived from patients
metastasis (H1650, H1299), and these two cell lines showed high basal levels of
Shh expression, suggesting that lung metastatic cells have the ability to undergo
EMT consistent with higher expression of Shh in vivo. Interestingly, the inhibition
of TGF-1-induced Shh signaling by pharmacological inhibitors or by siRNA,
decreased the ability of A549-M cells to migrate, invade and their colony-forming
ability, and these results are consistent with previous reports showing that the
activation of Shh signaling could increase invasion and metastasis (Bailey,
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Singh, and Hollingsworth 2007, 829-839;Feldmann et al. 2007, 21872196;Fukaya et al. 2006, 14-29;Teglund and Toftgard 2010, 181-208;Watkins et
al. 2003, 313-317;Yoo et al. 2008, 480-490). We have also shown that NIH 3T3
cells cultured in the presence of conditioned medium collected from A549-M cells
showed increased activation of hedgehog signaling, which suggests that TGF1-induced EMT can be mediated by the activation of Shh through both
autocrine, paracrine or juxtacrine mechanisms. More importantly, our data show
for the first time that TGF-1 induced EMT is mediated through up-regulation of
Shh because knock-down of Shh by siRNA significantly attenuated EMT
induction by TGF-1 treatment (Fig. 9B, C and D).
Next, I investigated the mechanism by which TGF-1 up-regulates Shh
gene. Since, understanding of this process would lead to specific therapeutic
treatments, at least, in a subset of NSCLC patients, thus, I investigated the
molecular mechanisms involving up-regulation of Shh gene expression in
NSCLC following TGF-1 treatment. I have characterized human Shh promoter
and its activation as well. Using combination of electrophoretic mobility shift
assay

(EMSA),

site-directed

mutagenesis,

luciferase

reporter

transient

transfection, and chromatin immunoprecipitation assays, I found that NF-B, was
activated in A549-M cells following TGF-β1 treatment, which activated the
expression of Shh gene (Fig. 16, 17, 18). Furthermore, I investigated the
posttranscriptional regulation of Shh by microRNAs (miRNA), which are negative
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regulators of gene expression at the posttranscriptional level, and which are
involved in tumorigenesis (Cho 2007, 60;Krutovskikh and Herceg 2010, 894904;Mocellin, Pasquali, and Pilati 2009, 70-80). To address this question, I
performed miRNA microarray using total RNA extrcated from A549 and A549-M
cells. Two miRNAs, miR-15a and miR-16, were found to be down-regulated in
A549-M cells compared to A549 cells. Both, miR-15a and miR-16 are located at
chromosome 13q14, and have been implicated in cell cycle control and
apoptosis. Both are frequently deleted or down-regulated in squamous cell
carcinomas and adenocarcinomas of the lung (Bandi et al. 2009, 55535559;Palamarchuk et al. 2010, 3916-3922). Interestingly, computational analysis
of miRNA profiles and their targets, using UCSC, TargetScan and PITA to predict
potential target genes of miR15a and miR-16, Shh 3' untranslated regions (3'
UTRs) was identified as a potential target. This is the first time documenting an
interesting correlation between miR15a and miR-16 and Shh 3' untranslated
regions (3' UTRs). Combining miRNA microarray data, and miRNA target genes
data, we found a good correlation between Shh gene up-regulation and the loss
of miR-15a and miR-16, suggesting that Shh up-regulation in A549-M can be
partly mediated by the loss of miR-15a and miR-16.
Interestingly, our data shows that phospho-Smad is constitutively
activated in A549-M cells even in the absence of TGF-1, suggesting a positive
feedback mechanism. Considering the reports that Shh treatment leads to
activation of Smads (Chow et al. 2010, G275-G282), our results suggest a
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visious cycle interconnecting TFG-1, NF-B, Shh, pSMAD and miRNAs. Thus, it
is our contention that initially TGF-1 activates NF-kB, which up-regulates Shh
expression, and in turn, Shh further activates TGF- signaling. These findings
would be helpful in the development of newer therapeutic strategies by targeting
not only Shh but also finding avenues by which one could re-express the lost
miRNAs to achieve reversal of therapeutic resistance to conventional
therapeutics, which would results in better treatment outcome.
Collectively, all of the above mentioned studies clearly suggest that Hh
signaling is a legitimate and novel target for the development of innovative
therapeutic strategies for the sensitization of invasive and metastatic cancer with
EMT or cancer stem-like cell characteristics to standard therapies in NSCLC. To
address this possibilty, A549-M and H1299, mesenchymal phenotypic cell lines,
were further treated with Hh inhibitor GDC-0449 (table. 4), for three days. Next,
cells were treated with cisplatin (Cis) or Erlotinib (Erlo), the epidermal growth
factor receptor-tyrosine kinase inhibitor (EGFR-TKI), and then cell viability was
assessed. Furthermore, Shh was knock-down by siRNA, then A549-M or H1299
were treated with Cis or Erlo, and cell viability was determined with the change in
the half-maximal inhibitory concentration (IC50). Data showed a significant
decrease in IC50 for both Cis and Erlo (Fig. 23, 24, 25), suggesting that Hh
inhibitor can be useful to sensitize resistant NSCLC cell lines with mesenchymal
phenotype to standard therapies. Next, I showed that Hedgehog inhibitor can
down-regulate EMT markers and up-regulate epithelial markers, in mesenchymal
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phenotype NSCLC cell lines, suggesting the possibility of EMT reversal by
hedgehog inhibitors and therefore the sensitization of these drug resistant cells to
conventional therapeutics could be clinically envisaged.
Based on existing evidence in the literature and based on my current
data, I propose a model where initially epithelial tumor cells chronically exposed
to TGF-1, excreted by either stromal cells, immune cells or the tumor cells
within the tumor microenvironment in vivo. This chronic TGF-1 exposure results
in the up-regulation of Shh both at the mRNA and at the protein levels, through
Smad-NF-B activation and down-regulation of specific miRNAs that targets Shh,
specificaly miR15a/16. Consequently, the activation of Hh signaling along with
other molecules, leads to the acquisition of EMT phenotype, which is responsible
for tumor cell aggressiveness, metastasis and drug resistance (Fig. 27).
Furthermore, I propose that activated hedgehog-signaling acts as feedback loop,
and activate Smad. Therefore, the inhibition of Shh signaling could be a useful
approach for reducing tumor aggressiveness in NSCLC, and as such, the
reversal of EMT could also be useful for re-sensitization of drug-resistant NSCLC
to conventional therapeutics, which would likely contribute to the improved
survival of patients who rightfully deserve better treatment outcomes.
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Figure 26. TGF-1 treatment up-regulates sonic hedgehog through
activation of Smad-NF-B signaling pathway, and also by
deregulation of miR-15a and miR-16. Shh up-regulation contributes
to EMT, invasiveness, metastasis, and that the loss of miRNAs
contributes to EMT and drug resistance. In addition, Shh upregulation may contribute to constitutive activation of SMAD.
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The American Cancer Society estimated that 222,520 Americans were
diagnosed with lung cancer and 157,300 died of lung cancer in 2010 (Jemal et
al. 2009, 225-249;Jemal et al. 2011, 69-90). The clinical outcome of patients
diagnosed with non-small cell lung cancer (NSCLC), the major lung cancer subtypes, is very poor, which calls for innovative research for finding novel
therapeutic targets and agents for better treatment outcome.
Emerging evidences have suggested that a phenomenon called Epithelialto-Mesenchymal Transition (EMT), which shares similar molecular characteristics
with cancer stem-like cells, contributes to lung cancer treatment failure. In view of
the fact that EMT process has been implicated in the two important biological
processes that are accountable for cancer-related deaths; the progression of
cancer cells to a distant organ, and the acquisition of resistance to conventional
cancer therapeutics (Leng et al. 2011, 145-155;Shih and Yang 2011;Zhang et al.

128

2011), needs further in-depth investigation. Therefore, further mechanistic
understanding of the role of EMT in lung cancer is very important, which was the
focus of my investigation.
In this study, I found for the first time that the induction of EMT by chronic
exposure of A549 NSCLC cells to TGF-1 (A549-M cells) led to the up-regulation
of sonic hedgehog (Shh) both at the mRNA and protein levels causing activation
of hedgehog signaling. These results were also reproduced in another NSCLC
cell line (H2030), and these results were further associated with the induction of
EMT phenotype. Induction of EMT was found to be consistent with aggressive
characteristics such as increased clonogenic growth, cell motility and invasion.
The aggressiveness of these cells was attenuated by the treatment of A549-M
cells with pharmacological inhibitors of Hh signaling in addition to Shh knockdown by siRNA. The inhibition of Hh signaling by pharmacological inhibitors led
to the reversal of EMT phenotype as confirmed by the reduction of mesenchymal
markers such as ZEB1 and Fibronectin, and induction of epithelial marker Ecadherin. In addition, knock-down of Shh by siRNA significantly attenuated EMT
induction by TGF-1.
Next, I examined the involvement of NF-B, as downstream of
TGF--receptor signaling, and in the up-regulation of Shh. I tested whether NFB activity could indeed be induced by TGF-1 in our model cell culture system.
To gain further mechanistic insight, I also tested whether the active NF-B could
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bind to consensus sequences on Shh promoter in cell free system. Additionally, I
determined the binding of the active NF-B to Shh promoter in the cell by CHIP
assay. Finally, I evaluated whether NF-B can activate Shh expression directly
using Shh promoter-luciferase reporter assays. The results clearly showed that
TGF-1 induced NF-B activity in NSCLC cell line A549. In addition, active NFB bound to its consensus sequences in the Shh promoter. Likewise, on CHIP
assay, I found that active NF-B bound to Shh promoter. Also, by utilizing
promoter-luceferase reporter assays, I confirmed that upon TGF-1 treatment
NF-B was physically bound to Shh promoter, and activated its transcription and
expression. Furthermore, I identified Shh gene as a target for miR15a and miR16, the two miRNAs that has been reported to be deleted or down-regulated in
NSCLCs.
To verify whether pharmacological inhibitors of Hh signaling
pathway can sensitize mesenchymal tumors with resistant phenotype to standard
therapy, and whether the sensitization of this tumor is a consequence of EMT
reversal caused by the inhibition of hh signaling. For such studies, I treated
NSCLCs A549-M, H1299, and H1650 cells with Hh inhibitors GDC-0449 for three
days, and then further treated these cells with either cisplatin or erlotinib for
different time points. My data showed an increase in NSCLCs sensitivity towards
cisplatin and erlotinib, suggesting that Hh inhibitors sensitized drug resistant
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mesenchymal phenotypic NSCLC tumor cells to standard therapy by reverting
EMT phenotype.
From these results, I conclude that chronic exposure of cancer cell in vivo
to TGF-1 leads to the acquisition of EMT phenotype as documented by this in
vitro study using NSCLC cells. The induction of EMT mediated by TGF-1 was in
part due to transcriptional activation of Shh which was due in part resulting from
the activation of NF-B and SMAD signaling in NSCLC cells, and causing tumor
cell aggressiveness in vitro and in animal model in vivo. The acquisition of EMT
resulted in therapeutic resistance and the treatment of these cells with Hh
signaling inhibitors (either Shh siRNA or synthetic inhibitor, GDC-0449) caused
reversal of EMT and sensitized cells to conventional therapeutics. Together,
these results suggest that reversal of EMT by Hh inhibitors would be useful for
achieving better treatment outcome in patients diagnosed with NSCLC.
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